Method of processing fibres and/or textile materials

FIELD: chemistry.

SUBSTANCE: invention relates to the encapsulation of active ingredients and to processing textile materials. Claimed are: a method of processing textile materials, containing microcapsules of active ingredients, fibres and/or textile materials, obtained from the said method, and their cosmetic or pharmaceutical application and/or their application as a repellent.

EFFECT: claimed invention makes it possible to increase the active ingredient stability for an acceptable number of washings.

16 cl, 6 dwg

 

Field of the INVENTION

The present invention is within the field of encapsulation of active ingredients and the treatment of textile materials. In particular, it relates to a method for treatment of textile materials and their cosmetic or pharmaceutical use or their use as an insect repellent.

The LEVEL of TECHNOLOGY

In the prior art various techniques are available for the encapsulation of cosmetic and/or pharmaceutical active ingredients in microcapsules. The technique of encapsulation consists of a coating on the active ingredients that are appropriate in various fields such as cosmetics, pharmaceuticals or foodstuffs, in the form of polymers of different nature to obtain particles with a size ranging between 1 micron to 1 mm [E. G. De Jalon, M. J. Blanco-Prieto, P. Ygartua, and S. Santoyo. Eur. J. Pharm. Biopharm. 56:183-187 (2003); M. A. Augustin and Y. Hemar. Chem. Soc. Rev., 2009, 38, 902-912; Sofia N. Rodrigues, Isabel Fernandes, Isabel M. Martins, Vera G. Mata, Filomena Baireiro, and Alirio E. Rodrigues. Ind. Eng. Chem. Res. 2008, 47 (12), 4142-4147; Stephan Drusch and Saverio Mannino. Trends in Food Science & Technology, 2009, 20, 237-244]. The microcapsule has a relatively simple morphological structure and is composed of two easily differentiable elements of the kernel that contains one or more active ingredients, and a polymeric shell which surrounds the core and thus protects the active and�gradient from the environment [W. Sliwka. Angew. Chem. Internal Edit. 14, 539 (1975)].

Among the methods for the encapsulation of active ingredients one of the most common is the encapsulation by the method of coacervation, which can be simple or complex coacervate. Koatservatsija based on the transfer of the polymer in an insoluble form in the colloidal system by the method of deposition of the coacervate particles, which encapsulates at least one active ingredient inside them. Among the mechanisms that induce the decrease of the solubility and therefore the deposition of coacervate are changes in temperature, pH modification, addition of precipitating polymer, salt or incompatible polymer. First active ingredient to be encapsulated, dispersed in liquid or solid form in a solution of the polymer or polymers that form the shell. After that, the formation of coacervate polymer or polymers induce one of the previous mechanisms, with its subsequent deposition on the active ingredient. Continuous deposition of the polymer due to a decrease of the free energy of the system due to the reduction of surface area during coalescence of polymer coacervate, which leads to the formation of a continuous shell around the encapsulated active ingredient. Next spend the solidification of the polymer shell coaters�in the way known as crosslinking, by adding Poperechnaya tools and optional cooling system. In the end carry out the separation of the microcapsules by centrifugation or filtration. As mentioned earlier, there are two types of coacervation, simple and complex. Simple coacervate occurs when the polymer precipitant is added to the system, usually a very hydrophilic substance that causes a separation into two phases with the formation of the coacervate. Examples of this procedure are described in documents such as ES 2009346, EP 052510 A1 and EP 0346879 A1. Complex koatservatsija is achieved when the two interact colloidal substances with opposite electrical charge, forming a complex, which has a lower solubility than that of the individual colloids, and which is deposited on the active ingredient to be encapsulated, forming a membrane that isolates the active ingredient. Examples of this procedure are described in documents such as WO 02/092217, WO 2005/105290, EP 1261421 A1 and EP 18737074 A1. Complex koatservatsija very dependent on pH, as the electrostatic interaction between two colloidal substances is carried out with the pH range in which one of the colloidal substances is in its cationic form acids, and other colloidal substance is in the form of its anion of the base.

One of applied�th microencapsulation, which aroused great interest in recent years, consists of treatment of fibers and textile materials to improve their appearance, luster, colour, smell and elasticity or to provide new fiber or textile material with functional capabilities such as treatment and/or care of skin, scalp and/or hair. Microencapsulation is a solution that is often used to associate the encapsulated active ingredient with fiber or textile material, as it allows you to extend the durability of the active ingredient in fiber or textile material, and which is slowly released onto the skin, the scalp and/or hair by destruction of microcapsules by pressure, heat, friction, osmosis or moistening the body. Thus, a continuous release of active ingredients on the skin, the scalp and/or hair is achieved through textile materials.

In the prior art there are various types of binding or connection of the microcapsules to the fibers or textile materials, for example one type of binding consists of binding the microcapsules to the fibers or textile materials by means of covalent bonds [W. Chao-Xia and S. Shui-Lin, Coloration Technology, 2004, 120, 14-18]. In a typical embodiment of the sheath microcap�uly is formed with cyclodextrins and preferably encapsulated active ingredients are fragrances or funds trapping odors. The fact that the microcapsules are associated or linked covalently, forcing them to remain on the fiber or textile material, and microcapsules of active ingredient to be encapsulated, can be re-loaded. The fundamental problem presented by this type of binding is that the creation of covalent bonds causes a modification in the chemical structure of the fiber, which can lead to the destruction and collapse of the textile material.

Another type of binding or connection of the microcapsules to the fibers or textile materials consists of the production of fibers in solutions where already present microcapsules containing active ingredients that need to be fixed on the fibers [Qi, No Ping, Xu Jun, and Wang Biomacromolecules, 2006, 7 (8), 2327-2330]. This type of binding or connection, which is limited exclusively to the active ingredients that should not penetrate the skin, such as insect repellents, and which, therefore, excludes any type of cosmetically and/or pharmaceutically active ingredient applied.

The last type of binding or connection of the microcapsules to the fibers or textile materials are ionic bonds between the microcapsule and fibers [Monitor R., L. Sanchez, F. Cases and M. A. Bonet, Textile Research Journal 2009, 79, 365-380]. The binding is invoked elek�astaticism interaction between the negative charges on the fibers of the textile material and the microcapsules, pre-cationization. The principal advantage of this type of linking or coupling, compared with the previous types are that he's not limited to one type of active ingredient and that this type of binding fibers or textile materials is not harmful to the mechanical properties of a textile material, as in the case of covalent bonding. In addition, and unlike previous types of binding of microcapsules containing the active ingredients, textile materials, there is a possibility for the end user himself to re-download the textile material is microencapsulated active ingredients.

However, one problem that occurs for fibers or textiles containing active ingredients, is low sternoptychidae as microcapsules that contain the active ingredients and the low resistivity of the active ingredients in the microcapsules, when they come in contact with surfactants detergents for textile materials. Surfactants detergents, which are suitable for dissolving dirt particles in textiles, is also able to penetrate into microcapsules, which are associated or connected with the textile material, and cause the solution�of active ingredient, which was encapsulated by its removal from textile material. Similarly, low sternoptychidae is the fact that of the microcapsules, and therefore, the active ingredient is lost during washing without the transfer of the active ingredient on the skin, the scalp and/or hair. As low sternoptychidae of microcapsules associated with fibers or textile materials, and the durability of active ingredients in the microcapsules is deeply affected by how the linking or connection of the microcapsules to the fibers or textile materials, and methods for producing microcapsules.

However, no single type of binding of the microcapsules with the previously described fibers or textile materials, known in the art is capable of retaining the encapsulated active ingredient in the textile material within a reasonable number of washings. Therefore, in the prior art there is a need for a method of treatment of textile materials, which will solve the aforementioned problem.

The patent application of Japan JP 50-20084 describes a method for binding the microcapsules containing dyes for fabrics. Microcapsules described in the above document, obtained by the method of coacervation, where, once formed a coacervate at pH 4.5, carry out crosslinking of the coacervate at pH . However, in this document there are no indications that the increase in pH at the stage of cross-linkage allows the production of microcapsules associated with a textile material, and the fact that the active ingredient contained in them is sustainable to a certain number of washes. In addition, the size of the microcapsules formed in this document is from 100 to 300 microns in diameter that substantially prevents the binding of microcapsules to a textile material and generation of uniform distribution on the textile material and good durability of the microcapsules to the textile material. On the other hand, this increased the size of the microcapsules does not prevent a surfactant detergents for textile materials penetrates into the microcapsules and dissolves the active ingredient, extracts of textile material.

Similarly, the document US 2800457 describes a method of complex coacervation microcapsules for where pH does not necessarily increase before cross-linking of the formed microcapsules. However, this document does not consider that microcapsules formed using this method, can be associated with the fibers or textile materials, not to mention that the microcapsules obtained in the textile material can be su� still connected with the textile material after drying at temperatures above 100°C.

Unexpectedly, the inventors of this invention found a method for the treatment of textile materials, containing at least one active ingredient that is associated with the fibers and/or textile materials, in which the increase in pH, as soon as coacervate microcapsules were formed and before cross-linking, allows the production of fibers and/or textile materials, containing at least one active ingredient, where the active ingredient is retained in the fibers and/or textile materials within a reasonable number of washings.

Description of the INVENTION

The present invention relates to a method for the treatment of fibers and/or textile materials, which solves the previously described problems.

According to the first aspect of the present invention describes a method of processing fibers and/or textile materials, containing at least one active ingredient, which comprises the following steps:

a) dissolution of two hydrophilic colloids in the solvent in which they are soluble, and adding at least one active ingredient to form a suspension of the active ingredient in this solution,

(b) adjusting pH and/or breeding of previous slurry to cause coacervation colloids and their deposition on the active ingredient, which is thus encapsu�varies,

c) increasing the pH of the slurry and adding Poperechnaya means for solidification of the formed microcapsules,

(d) cationization microcapsules with a polymer or cationic monomer,

(e) the connection or binding of microcapsules to the fibers and/or textile materials,

(f) drying the fibers and/or textile materials.

The sequential order of the steps a), b), C), (d), (e) and (f). Not necessarily between stages b) and c) there was an intermediate stage of cooling of the microcapsules obtained in step b). This method of treatment of fibers and/or textile materials provides the possibility of uniform distribution of the microcapsules on the surface of the fibers and/or textile material because of the small size of the microcapsules. Moreover, the small size of the microcapsules also leads to greater penetration of microcapsules in the fiber and/or textile material, which leads to greater durability after washing. On the other hand, the polymer shell of the microcapsules formed using hydrophilic colloids, is very hard and compacted, making stable microcapsules after drying, the fibers and/or textile material.

In the context of this invention, the processing of the fibers and/or textile materials provides the possibility that the receive fibers and/or textile materials with Fung�national characteristics, such as cosmetic, pharmaceutical or insect repellents.

In a specific embodiment of the two hydrophilic colloid selected, without limitation, from the group formed by the following: proteins, polysaccharides, polyesters, polyacrylates, polycyanoacrylate, polyethylene glycol, copolymers and/or mixtures thereof. Preferably, proteins and polysaccharides are selected, for example and without limitation, from the group formed by the following: gelatin, albumin, β-lactoglobulin, milk whey protein, pea protein, potato protein, protein feedstuff beans, wheat protein, bovine serum albumin, poly-L-lysine, soy protein, Caseinates, casein, soya glycine, sodium alginate, wheat starch, corn starch, methylcellulose, ethylcellulose, hydroxypropylmethyl cellulose (HPMC), cellulose nitrate, carboxymethyl cellulose, gum Arabic, xanthan gum, Mesquite gum, guar gum, carragenan, tragacantha gum, arabinogalactan, galactomannans, sodium hexametaphosphate, exopolysaccharides B40, carboxymethyl sodium, pectin, methoxylation, agar, dextran, chitosan, acetobutyrate cellulose, acatitla cellulose, acrylic derivatives and polyesters, such as poly-ε-caprolactone, Zein, phthalate of hydroxypropylmethylcellulose, acetonuria of hydroxypropylmethylcellulose, polyvinylacetate, poly(p-deok�anon), poly(δ-valerolactone), poly(β-hydroxybutyrate), copolymers of poly(β-hydroxybutyrate) and β-hydroxyvalerate, poly(β-hydroxypropionate), copolymers of methylacrylate acid (Eudragit®L and S), copolymers of dimethylaminoethylmethacrylate (Eudragit®E) copolymers of trimethylammoniumchloride (Eudragit®RL and RS), polymers and copolymers of lactic and glycolic acid, polymers and copolymers of lactic and glycolic acid and polyethylene glycol and mixtures thereof.

In another specific embodiment of the hydrophilic colloid, the solvent is water or an aqueous solution.

In another specific embodiment, the implementation of stage a) of the method of the present invention is carried out at a temperature preferably above 40°C and more preferably at above 50°C.

In another specific embodiment of the bring the pH at the stage b) of the method of the present invention depends on the combination of colloids used for the formation of coacervate, but is preferably acidic pH, from 3 to 5.5 and more preferably from 4 to 5.

In another specific embodiment of the temperature at which the microcapsules are cooled between step b) and step C) is lower than 30°C and preferably equal to or lower than 10°C.

In another specific embodiment, the implementation of increasing the pH in step (C) of the method of the present invention is a pH of from 6.5 to 3, preferably pH 7 to 10.

In another specific embodiment of Poperechnaya tool phase C) of the method of the present invention are selected, for example and without limitation, from the group formed by the following: aldehydes, such as glutaraldehyde or formaldehyde; transglutaminase, derived methylenebisacrylamide, N,N-methylenebisacrylamide, N,N-(1,2-dihydroxyethylene)bisacrylamide, derivatives of etilenglikolevykh, etilenglikolevye, dietilenglikoluretan, tetraethylorthosilicate, etilenglikolevykh, diethylethylenediamine, Triethylenetetramine, sodium tripolyphosphate, esters of N-hydroxysuccinimide and/or imidiately.

In another specific embodiment of the size of the microcapsules after cross-linkage (C) is less than 30 microns, preferably less than 10 microns.

In another specific embodiment of the cationic polymer used to cationization microcapsules in step (a) of the method of the present invention, are selected, for example and without limitation, from the group formed by the following: cationic cellulose derivatives, such as kvaternikova hydroxyethylcellulose, which may be purchased under the name Polymer JR 400™ from Amerchol; cationic starch; copolymers of diallylamine acrylamide and salts; quaternio�ƈ polymers of vinylpyrrolidone/vinylimidazole, such as Luviquat™ (BASF); condensation products of polyglycols and amines; polymers and copolymers of polyquaternium; polymers having the name of mercuty of polyquaternium-6, polyquaternium-7, polyquaternium-16, polyquaternium-10; copolymers of polyquaternium-4; dicocoylethylenediamine, graft copolymers with a cellulose skeleton and Quaternary ammonium groups; quaternion collagen polypeptides, such as hydroxypropyltrimonium hydrolyzed collagen (Lamequat™ from Grunau); quaternion wheat polypeptides; polyethyleneimine; cationic silicone polymers, such as midamerican or silicone quaternium-22; copolymers of adipic acid and (Cartaretine™ from Sandoz); copolymers of acrylic acid with dimethyldiallylammonium (Merquat™ 550 from Chemviron); cationic chitin derivatives such as chitosan and its derivatives; condensation products of cationic dehalogenation, such as dibromobutane with misdialling; bis-dimethylamino-1,3-propane; cationic derivatives of the guar gums, such as guar-hydroxypropyltrimonium, Jaguar™ CBS, Jaguar™ C-17, Jaguar™ C-16 from Celanese; polymers of Quaternary ammonium salts, such as Mirapol™ A-15, Mirapol™ AD-1, Mirapol™ AZ-1 from Miranol; quaternion natural polymers polysaccharide derivatives, such as azarosa; cationic proteins selected from gelatin�, gum Arabic; cationic polymers from the group formed by the following: polyamides, polycyanoacrylates, polylactic acid called PLA, polyglycolide, polyaniline, polypyrrole, polyvinylpyrrolidone, polymers and copolymers of aminosilicone, polystyrene, polyvinyl alcohol, copolymers of polystyrene and maleic anhydride, methyl vinyl ether, epoxy resins and copolymers of styrene and methyl methacrylate; dimethylaminoethylacrylate, cationic polyacrylates and polymethacrylates such as Eudragit™ RL 30 D from Rohm; polyamine derivatives, optionally substituted derivatives are members of a polyethylene glycol; polyaminoamide under conditions of pH where they are cationic; polyethyleneimine; quaternion derivatives of polyvinylpyrrolidone (PVP) and hydrophilic urethane polymers, and any mixture of the above-mentioned cationic groups.

In another specific embodiment of the cationic polymer used to cationization microcapsules in step (d) of the method of the present invention are selected, for example and without limitation, from the group formed by the following: , cerimoniale, , , babassuamidopropalkonium, trigonometrically, cetrimonium tosylate, aluminoborosilicate, quaternium-2, quaternium-91, delaure-4 demonomania, distearyldimonium, PEG-5 hydrogenated tallow amine, trimethylsilylpropyne soy demonomania, Minoxidil, capilarity, hydroxypropyltrimonium hydrolyzed corn starch, cysteine hydrochloride, Biotin, carnitine, ceramide 2, ceramide 1, ceramide 6, alanine, cocamidopropylbetaine, cystine, cocodimethylamine hydrolyzed rice protein, DEA-isostearate, DEA-lauramidopropyl, disodium lauriemodel.

In another specific embodiment of the connection or binding of microcapsules to the fibers and/or textile materials in step (e) of the method of this invention is carried out using a depletion of the bath, using plyaski or by spraying. In the context of this invention the expression "binding" and "connection" is applicable without distinction.

In another specific embodiment of the drying of the fibers and/or textile materials according to the method of this invention is carried out for at least 2 minutes at temperatures above 100°C, preferably equal to or higher than 120°C.

The method of this invention solves the problem of loss of active ingredient in the fibers and/or textile materials after they are dried. The stability of the active ingredient within a reasonable number of washings of the fibers and/or textile m�materials means that there is more than 5% of the active ingredient in the fibers and/or textile materials after 10 washes, and more preferably more than 10% after 10 washings. The Laundry fibers and/or textile materials is carried out either manually in accordance with ISO 105 C06 A1S, or using machines, according to standard UNE-EN 6330:2001.

The method of this invention can be applied to the textile fibres before or after their production, and it should be understood that the linking of textile materials means you connect with the textile fibres. Textile fibres can be natural or synthetic and selected, for example, and without limitation, from the group formed by the following: wool, cotton, silk, nylon, cellulose, polyamide or polyester, among others. In the present invention, the textile material is understood as woven fabric, nonwoven fabric, apparel, and medical devices. Examples of woven fabrics, non-woven materials, clothing, and medical devices can be found in the literature and they are known in the art ("Impregnating Fabrics With Microcapsules", HAPPI May 1986; Int. J. Pharm. 2002, 242, 55-62; "Biofunctional Textiles and the Skin" Curr. ProbI: Dermatol. 2006 v.3; J. Cont. Release 2004, 97, 313-320). Among the preferred textile materials woven fabrics, non-woven materials, clothing, and medical devices are bandages, gauze, t-shirts, socks, tights, n�INEE linen, belts, gloves, diapers, sanitary napkins, dressings, bedspreads, wipes, hydrogels, adhesive patches, neagative patches, micro-electric patches and/or face masks.

In another specific embodiment, the implementation of an active ingredient selected from the group formed by the following: the active ingredients and/or cosmetic and/or dermofarmatsevtiki auxiliary substances and insect repellents. In particular, active ingredients and/or cosmetic and/or dermofarmatsevtiki auxiliary substances selected, for example, and without limitation, from the group formed by the following: surfactant, wetting means or substances that retain moisture, moisturizers or emollients, agents that stimulate the healing process, facilitate the healing means, stimulating re-epithelialization, a means to facilitate re-epithelialization, means that synthesize dermal or epidermal macromolecules, sealing and/or reducing the density and/or restructuring funds, growth factors, cytokines, tools, acting on capillary circulation and/or microcirculation, artiglierie tools, traps free radicals and/or agents against atmospheric pollution, trap reactive carbonyl species, means�and, inhibiting 5α-reductase, and means inhibiting lysyl - and/or prolylhydroxylase, agents that stimulate the synthesis of defensin, bactericidal agent, and/or a bacteriostatic agent, and/or antimicrobial, and/or germicidal means, and/or fungicidal agents, and/or fungistatic funds, and/or inhibiting pathogenic microorganisms, antiviral agents, antiparasitic agents, antihistamines, means inhibiting NO-synthase, means for peeling or keratolytic remedies and/or remedies to exfoliate, comedolytics funds, antipsoriatic drugs, anti-dandruff, anti-inflammatories and/or analgesics, anaesthetics, anti-wrinkle and/or anti-aging products, cosmetic deodorant and/or absorbent and/or masking body odour deodorants, tools, antiperspirants, fragrances and/or scented oils, and/or selected aromatic compounds, the funds are antioxidants that means that inhibit vascular permeability, hydrolytic epidermal enzymes, bleaching or depigmenting skin, means inhibiting the enzymes the collapse of sweat, means capable of filtering UV rays, the funds that stimulate or regulate the differen�zirovka keratinocytes, antipruritic, means which stimulate or inhibit the synthesis of melanin, the colouring means, bronzer, agents that stimulate the proliferation of melanocytes, liquid propellants, vitamins, amino acids, proteins, biopolymers, gelling polymers, drugs to relax the skin, means to reduce or treat bags under eyes, remedies for the treatment and/or care of sensitive skin, tightens pores funds, means of regulating the production of sebum, anti stretch marks, lipolytic funds or a means of stimulating lipolysis, venotonizirutee funds, cellulite remedies, sedatives, tools, acting on cell metabolism, a means to improve dermaline-epidermal junction, means of inducing hair growth or slowing down the hair loss, the means of inhibiting or retarding the growth of body hair, a means of stimulating the synthesis of heat shock proteins, muscle relaxers, tools, inhibiting muscle contraction, means inhibiting the aggregation acetylecholine receptors, anticholinergic means, inhibiting elastase, the means of inhibiting a matrix metalloproteinase, a chelating means, plant extracts, essential oils, extracts from marine products, mineral with�Lee, cell extracts, emulsifying means, means stimulating the synthesis of lipids and components of the stratum corneum (ceramides, fatty acids, etc.), funds received from the bio-enzymatic method of and/or mixtures thereof. The nature of these active ingredients and/or cosmetic and/or alimentary auxiliary substances may be synthetic or natural; such as plant extracts, or come from a biotechnological method or of a combination of synthetic method and biotechnological way. Additional examples can be found in the CTFA International Cosmetic Ingredient Dictionary &Handbook, 12th Edition (2008). In the context of this invention under biotechnological method know any method that produces an active ingredient or a part of the body or its parts.

In a specific embodiment, the implementation of a wetting agent or a substance that retains moisture, moisturizer or softener is selected, for example, and without limitation, from the group formed by the following: polyhydric alcohols and polyethers, such as glycerol, Ethylhexylglycerin, capriglione, pentylindol, butyleneglycol, propylene glycol and their derivatives, triethylene glycol, polyethylene glycol, glycereth-26, sorbet-30; panthenol; pyroglutamyl acid and its salts and derivatives; amino acids such as serine, Proline, alanine, glutamate or arginine�in; ectoin and its derivatives; N-(2-hydroxyethyl)acetamide; N-lauroyl-pyrrolidone carboxylic acid; N-lauroyl-L-lysine; N-alpha-benzoyl-L-arginine; urea; creatine; α - and β-hydroxy acids such as lactic acid, glycolic acid, malic acid, citric acid or salicylic acid, and their salts; polyglycerylmethacrylate; sugars and polysaccharides such as glucose, isomerate of saccharide, sorbitol, pentaerythritol, Inositol, xylitol, trehalose and derivatives thereof, sodium glucuronate, carrageenate (Chondrus crispus) or chitosan; glycosaminoglycans, such as hyaluronic acid and its derivatives; aloe Vera in any of its forms; honey; soluble collagen; lecithin and phosphatidyl choline; ceramides; cholesterol and its esters; tocopherol and its esters, such as Tocopheryl acetate or Tocopheryl linoleic acid; long-chain alcohols such as Cetearyl alcohol, stearyl alcohol, cetyl alcohol, alerby alcohol, societally alcohol or octadecan-2-ol; esters of long chain alcohols, such as laurolactam, myristylated or C12-C15alkylbenzoates; fatty acids such as stearic acid, ezoterikova acid or palmitic acid; polyunsaturated fatty acids (PUFA); sorbitan, such as sorbitanoleat; glycerides, such as glycerylmonostearate, glycerylmonostearate, glycerol�teertstra or triglyceride of Caprylic and Caproic acid; esters of sucrose such as sucrose palmitate or sucrose oleate; esters of butyleneglycol, such as dicaprylate and dicaprate; esters of fatty acids, such as isopropylacetate, isobutylacetate, asiatischer, isopropylene, exellent, decillia, tetralite, di-n-butylsilane, isopropyl myristate, isopropylpalmitate, isopropylmalate, bodystart, Boutilimit, isopropylidene, 2-ethylhexylamine, 2-ethylhexylamine, decillia, myristylated; squalene; mink oil; lanolin and its derivatives; acetylated lanolin alcohols; silicone derivatives such as cyclomethicone, Dimethicone or dimethylpolysiloxane; Antarcticine®[INCL: enzyme extract Pseiidoalteromonas] or acetyl-glutamyl-Oh-alanyl-isoleucine, acetyl-arginyl-phenylglycyl-phenylglycine or acetyl-arginyl-6-aminohexanoic-alanine, available from Lipotec, petrolatum; mineral oil; mineral and synthetic waxes; beeswax (white wax); paraffin; or waxes and oils of vegetable origin, such as candlelike wax (Euphorbia cerifera), Carnauba wax (Copernicia cenifera), Shea butter (Butirospermum parkii), cocoa butter (Theobroma cacao), castor oil (Ricinus communis), sunflower oil (Helianthus annuus), olive oil (Olea europaea), coconut oil (Cocos nucifera), oil palm (Elaeis guineensis), wheat germ oil (Triticum vulgre), sweet almond oil (Prunus amygdalus dulces), oil, musk rose (Rosa moschata), soybean oil (Glycine soja) oil from the seeds of grapes (Vitis vinifera), calendula oil (Calendula officinalis), jojoba oil (Simmonsis chinensis), mango butter (Mangifera indica), avocado oil (Persea gratissima) and/or mixtures thereof, among others.

Similarly, in another specific embodiment of the means of stimulating the healing process, facilitate the healing tool, a means of stimulating the re-epithelialization and/or promote re-epithelialization tool selected, for example, and without limitation, from the group formed by the following: extracts Aristoloquia clematis, Centelia asiatica, Rosa moschata, Echinacea angustifolia, Symphytum officinale, Equisetum arvense, Hypericum perforatum. Mimosa tenuiflora, Persea gratisima, Prunus africanum, Tormentilla erectea, Aloe vera, Polyplant®Epithelizing [INCL: Calendula Officinalis, Hypericum Perforatum, Chamomilla Recutita, Rosmarinus Officinalis], available from KProvital, Cytokinol®LS 9028 [INCL: hydrolyzed casein, hydrolyzed yeast protein, lysine HCl], available from Laboratories Serobioiogiques/Cognis or Deisner®[INCL: extracg grains of Zea May (corn)], commercially available from Coletica/Engelhard/BASF, allantoin, cadherin, integrins, selectins, receptors hyaluronate the zealots, immunoglobulins, fibroblast growth factor, growth factor connective tissue growth factor, platelet growth factor vascular epithelium, epidermal growth factor, insulin-like growth factor, growth factors Coeur�of timotsitov, colony-stimulating factors, transforming growth factor beta, tumor necrosis factor-alpha, interferons, interleukins, matrix metalloproteinases, receptor promoteinteroperablity, Antarcticine®[INCL: enzyme extract of Pseudoalteromonas], Decorinyl®[INCL: Tripeptide-10 citrulline], Trylagen®[INCL: enzyme Pseudoalteromonas extract, hydrolyzed wheat protein, hydrolyzed soy protein, Tripeptide-10 citrulline, Tripeptide-1], acetyl-glutamyl-Oh-alanyl-isoleucine, acetyl-arginyl-phenylglycyl-phenylglycine or acetyl-arginyl-6-aminohexanoic-alanine, available from Lipotec, among others.

In a particular embodiment of the means of stimulating the synthesis of dermal or epidermal macromolecules, selected, for example, and without limitation, from the group formed by the following: agents that stimulate the synthesis of collagen, agents that stimulate the synthesis of elastin, agents that stimulate the synthesis decorin, a means of stimulating the synthesis of laminin, a means of stimulating chaperone synthesis, agents that stimulate the synthesis of hyaluronic acid, agents that stimulate the synthesis of aquaporins, agents that stimulate the synthesis of fibronectin, means inhibiting collagen breakdown, means inhibiting the breakdown of elastin, means inhibiting semipretioase such as leukocytosis or cathepsin G, means�and, stimulating fibroblast proliferation, agents that stimulate the proliferation of adipocytes, agents that stimulate the differentiation of adipocytes, a means of stimulating angiogenesis, agents that stimulate the synthesis of glycosaminoglycans, means DNA repair and/or DNA-protective means, for example, and without limitation, extracts of Centella asiatica, Saccharomyces cerevisiae, Solatium tuberosum, Rosmarinus officinalis, Vaccinium angustifolium extract, algae Macrocystis pyrifera, Padina pavonica, an extract of the following plants: soybean, licorice root, flax, sage, red clover, kakkon-to, white Lupin, hazelnut extract, corn extract, yeast extract, the extract of beech shoots, bean seed extract, extract of plant hormones such as gibberellins, auxins or cytokinins, among others, or an extract of the zooplankton in the salt lakes, the product of fermentation of milk using Lactobacillus Bulgaricus, asiaticosides and derivatives thereof, vitamin C and derivatives thereof, cinnamic acid and its derivatives, Matrixyl®[INCL: polymethylpentene-3], Matrixyl®3000 [INCL: palmitostearate-3, palmitoylated] or Biopeptide CL™ [INCL: glyceryltrinitrate, propylene glycol, palmitoylated], commercially available from Sederma, Antarcticine®(INCL: enzyme extracts of Pseudomonas], Decorinyl®[INCL: Tripeptide-10 citrulline], Serilesine®[INCL: Hexapeptide-10], Lipeptide [INCL: hydrolyzed vegetable protein], Aldenine [INCL: hydrolyzed wheat protein, hydrolyzed soy protein, Tripeptide-1], Peptide AC29 [INCL: acetyltributyl-30 citrulline], acetyl-arginyl-phenylglycyl-tryptophyl-phenylglycine, acetyl-arginyl-phenylglycyl-valyl-glycine or acetyl-arginyl-phenylglycyl-valyl-phenylglycine, commercially available from Lipotec, Drieline®PF [INCL: yeast beta-glucan], commercially available from Alban Muller, Phytovityl With®[INCL: water, extract of Zea Mays], available from Solabia, Collalift®[INCL: hydrolyzed licorice extract], available from Coletica/Engelhard, Phytocohesine® PSP [presumably INCL: beta sitosterolemia sodium], available from Seporga, minerals such as calcium, among other things, retinoids and their derivatives, isoflavones, carotenoids, in particular lycopene, pseudodipeptides, retinoids and derivatives such as retinol or remineralised, among other things, or heparinoid, among others.

In a particular embodiment of the means of stimulating the synthesis of dermal or epidermal macromolecules, selected, for example, and without limitation, from the group formed by the following: agents that stimulate the synthesis of collagen, agents that stimulate the synthesis of elastin, agents that stimulate the synthesis decorin, a means of stimulating the synthesis of laminin, a means of stimulating chaperone synthesis, agents that stimulate the synthesis of hyaluronic acid�, agents that stimulate the synthesis of aquaporins, agents that stimulate the synthesis of fibronectin, means inhibiting collagen breakdown, means inhibiting the breakdown of elastin, means inhibiting semipretioase such as leukocytosis or cathepsin G, a means of stimulating fibroblast proliferation, agents that stimulate the proliferation of adipocytes, agents that stimulate the differentiation of adipocytes, a means of stimulating angiogenesis, agents that stimulate the synthesis of glycosaminoglycan, means DNA repair and/or DNA-protective means, for example, and without limitation, extracts of Centella asiatica, Saccharomyces cerevisiae, Solanum tuberosum, Rosmarinus officinalis, Vaccinium angustifolium, algae extract Macrocystis pyrifera, Padina pavonica, an extract of plants such as soy, licorice, flax, sage, red clover, kakkon-to, white Lupin, hazelnut extract, corn extract, yeast extract, extract of beech shoots, bean seed extract, extract of plant hormones such as gibberellins, auxins or cytokinins, among others, or an extract of the zooplankton in the salt lakes, the product of fermentation of milk using Lactobacillus Bulgaricus, asiaticosides and derivatives thereof, vitamin C and derivatives thereof, cinnamic acid and its derivatives, Matrixyl®[INCL: polymethylpentene-3], Matrixyl®3000 [INCL: palmitostearate-3, palmitoylated] or Biopeptide CL™ [INCL: glicerio�methacrylat, propylene glycol, palmitoylated], commercially available from Sederma, Antarcticine®[INCL: enzyme extracts of Pseudomonas], Decorinyl®[INCL: Tripeptide-10 citrulline], Serilesine®[INCL: Hexapeptide-10], Lipeptide [INCL: hydrolyzed vegetable protein], Aldenine®[INCL: hydrolyzed wheat protein, hydrolyzed soy protein, Tripeptide-1], Peptide AC29 [INCL: acetyltributyl-30 citrulline], acetyl-arginyl-phenylglycyl-tryptophyl-phenylglycine, acetyl-arginyl-phenylglycyl-valyl-glycine or acetyl-arginyl-phenylglycyl-valyl-phenylglycine, commercially available from Lipotec, Drieline®PF [INCL: yeast beta-glucan], commercially available from Alban Muller, Phytovityl With®[INCL: water, extract of Zea Mays], available from Solabia, Collalift® [INCL: hydrolyzed licorice extract], available from Coletica/Engelhard, Phytocohesine®PSP [presumably INCL: beta sitosterolemia sodium], available from Seporga, minerals such as calcium, among other things, retinoids and their derivatives, isoflavones, carotenoids, in particular lycopene, pseudodipeptides, retinoids and derivatives such as retinol or remineralised, among other things, or heparinoid, among others.

In a particular embodiment of the means, inhibiting elastase, selected, for example, and without limitation, from the group formed by the following: Elhibin®[INCL: soybean protein glycine (soybeans)] Preregen ®[INCL: protein glycine soya (soybean), oxidoreductase] or Regu®-Age [INCL: hydrolyzed rice bran protein, soybean protein glycine (soybeans), oxidoreductase], available from Pentapharm/DSM, Juvenesce [INCL: ethoxydiglycol and Caprylic triglyceride, retinol, ursolic acid, phytonadione, ilomastat], Micromerol™ [INCL: extract Pyrus Malus], extract of Heather [INCL: Calluna Vulgaris extract], Extracellium®[INCL: hydrolyzed potato protein] or Flavagrum™ PEG [INCL: PEG-6 isostearate, gespeichert], available from Coletica/Engelhard/BASF, Proteasyl®TP LS8657 [INCL: Pisum Sativum extract], available from Laboratoires Serobiologiques/Cognis, acetyl-arginyl-phenylglycyl-tryptophyl-phenylglycine, acetyl-arginyl-phenylglycyl-valyl-glycine or acetyl-arginyl-phenylglycyl-valyl-phenylglycine, commercially available from Lipotec, Sepilift DPHP [INCL: dipalmitoylphosphatidyl], commercially available from SEPPIC, Vitaderm®[INCL: alcohol, water, glycerin, hydrolyzed rice protein extract, Ilex Aquifolium, ursolic sodium, oleanolic sodium], commercially available from Rahn, Gatuline®Age Defense 2 [INCL: seed extract, Juglans Regia (walnut)], commercially available from Gattefosse, IP2000 [INCL: dextran, cryptanalytical-2], commercially available from EV and Atrium, Radicaptol [INCL: propylene glycol, water, Passiflora Incarnata flower extract, leaf extract Ribes Nigrum (black currant) leaf extract Vitis Vinifera (grape)], access�th on sale from Solabia or ViaPure™ Boswellia [INCL: extract of frankincense (Boswellia Serrata)], available from Soliance, among others.

In a specific embodiment, the implementation of a means of inhibiting a matrix metalloproteinase selected, for example, and without limitation, from the group formed by the following: ursolic acid, isoflavones such as genistein, quercetin, carotenoids, lycopene, soy extract, cranberry extract, rosemary extract, Trifolium pratense (red clover) extract, Phormium tenax (new Zealand flax) extract, kakkon-to extract, sage extract, retinol and its derivatives, retinoic acid and its derivatives, sapogenins, such as diosgenin, hecogenin, smilagenin, sarsapogenin, tigogenin, yamogenin and wagenin, among other things, Collalift®[INCL: hydrolyzed licorice extract], Juvenesce [INCL: ethoxydiglycol and Caprylic triglyceride, retinol, ursolic acid, phytonadione, ilomastat] or EquiStat [INCL: fruit extract Pyrus Malus extract, glycine soya seeds], available from Coletica/Engelhard, Pepha®-Timp [INCL: Oligopeptide-20], Regu-Age [INCL: hydrolyzed rice bran protein, glycine soybean protein, oxidoreductase] or Colhibin [INCL: hydrolyzed rice protein], available from Pentapharm, Lipeptide [INCL: hydrolyzed vegetable protein] or Peptide AC29 [INCL: acetyltributyl-30 citrulline], available from Lipotec, Litchiderm™ [INCL: extract of the pericarp of Litchi Chinensis] or Arganyl™ [INCL: leaf extract Argania Spinosa], available in sales� from Laboratories Serobiologiques/Cognis, MDI Complex®[INCL: glycosaminoglycans] or ECM-Protect®[INCL: water (water), dextran, Tripeptide-2], commercially available from Atrium Innovations, Dakaline [INCL: extract Prunus amygdalus dulcis, Anogeissus leiocarpus bark], available from Soliance, Homeostatine [INCL: Enteromorpha compressa, Caesalpinia Spinosa], available from Provital, Timp-Peptide [presumably INCL: acetyl Hexapeptide] or ECM Moduline [presumably INCL: palmitoylated], available from Infinitec Activos, IP2000 [INCL: dextran, cryptanalytical-2], available from Institut Europeen de Biologie Cellulaire, Actimp 1.9.3®[INCL: hydrolyzed lupine protein], available from Expanscience Laboratories, Vitaderm®[INCL: alcohol, water (water), glycerin, hydrolyzed rice protein, extract liex Aquifolium, ursolic sodium, oleanolic sodium], commercially available from Rahn, adapalene, tetracyclines and their derivatives, such as minocycline, rolitetracycline, chlortetracycline, metatsiklina, oxytetracycline, doxycycline, demeclocycline and their salts, batimastat [W; [4-(N-hydroxyamino)-2R-isobutyl-3S-(thiophene-2-altimeter)succinyl]-L-phenylalanine-N-methylamide], marimastat [W; [2S-[N4(R*),2R*,3S]]-N4[2,2-dimethyl-1-[methylaminomethyl]propyl]-N1,2-dihydroxy-3-(2-methylpropyl") butadiene], among others.

In a particular embodiment of the sealing and/or reducing density and/or restructuring tool selected, for example, and without limitation, from the group, obra�agreed as follows: extracts Malpighia punicitolia, Cynara scolymus, Gossypium herbaceum, Aloe Barbadensis, Panicum miliaceum, Morus nigra, Sesamum indicum, Glycine soja, and Triticum vulgare, Pronalen®Refirming HSC [INCL: Triticum vulgare, Silybum Marianum, Glycine Soy, Equisetum Arvense, Alchemilla Vulgaris, Medicago Sativa, Raphanus Sativus] or Polyplant®Refirming [INCL: Echinacea, Centella asiatica, fucus, fenugreek], available from Provital, Lanablue®[INCL: sorbitol, algae extract], commercially available from Atrium Innovations, Pepha®-Nutrix [INCL: natural nutrient factor], available from Pentapharm, or plant extracts, which contain isoflavones, Biopeptide EL™ [INCL: palmitoylated], Biopeptide CL™ [INCL: palmitoylated], Vexel®[INCL: water (water), propylene glycol, lecithin, caffeine, palmitoylcarnitine], Matrixyi®[INCL: polymethylpentene-3], Matrixyl®3000 [INCL: palmitostearate-3, palmitoylated] or Bio-Bustyl™ [INCL: glyceryltrinitrate, lastanosa gum, water (water), propylene glycol, glycerin, PEG-8, palmitoylated], commercially available from Sederma, Dermosaccharides®NS [INCL: glycerin, water (water), glycosaminoglycans, glycogen], Aglycal®[INCL: mannitol, cyclodextrin, glycogen, leaf extract Aratostaphylos Uva Ursi], Cytokinol®LS [INCL: hydrolyzed casein, hydrolyzed yeast protein, lysine HCL] or Firmiderm®LS9120 [INCL: extract of the leaves of Terminalia Catappa, flower extract Sambucus Negra, polyvinylpyrrolidone, tannic acid], available from Laboratoires erobiologiques/Cognis, Liftline®[INCL: hydrolyzed wheat protein], Raffermine®[INCL: hydrolysed soy flour] or Ridulisse With®[hydrolyzed soy protein], available from Siiab, Serilesine®[INCL: Hexapeptide-10], Decorinyl™ [INCL: Tripeptide-10 citrulline], Trylagen®[INCL: enzyme Pseudoalteromonas extract, hydrolyzed wheat protein, hydrolyzed soy protein, Tripeptide-10 citrulline, Tripeptide-1], available from Lipotec, Ursolisome®[INCL: lecithin, ursolic acid, atelocollagen, xanthan gum, chondroitin sulfate sodium] or Collalift®[INCL: hydrolyzed licorice extract], available from Coletica/Engelhard, Syn®-Coll [INCL: palmitoleate-5], available from Pentaphann, Hydriame®[INCL: water (water), glycosaminoglycans, gum sclerotium], commercially available from Atrium Innovations or IP2000 [INCL: dextran, cryptanalytical-2], available from Institut Europeen de Biologie Cellulaire, among others.

In a particular embodiment of anthicidae tool selected, for example, and without limitation, from the group formed by the following: extracts of Vaccinium angustifolium, rich in ergothioneine and its derivatives, lysine, Aldenine®[INCL: hydrolyzed wheat protein, hydrolyzed soy protein, Tripeptide-1], Vilastene™ [INCL: lysine HCl, lecithin, Tripeptide-10 citrulline], dGlyage™ [INCL: lysine HCl, lecithin, Tripeptide-9 citrulline] or Eyeseryl®[INCL: acetylator�peptide-5], available from Lipotec, hydroxystyrene and their derivatives, resveratrol or 3,3',5,5'-tetrahydrogestrinone, among others.

In a particular embodiment of the trap free radicals and/or remedy against atmospheric pollution, and/or trap reactive carbonyl species selected, for example, and without limitation, from the group formed by the following: tea extract, olive leaf extract, gold extract, Rosmarinus officinalis or extract of Eichhornia crassipes, benzopyrene, vitamin C and its derivatives, vitamin E and derivatives thereof, in particular Tocopheryl acetate, ascorbicacid, phenols and polyphenols, in particular tannins, tannic acid and ellagic acid, gallocatechin, anthocyanins, chlorogenic acid, stilbene, indoles, derivatives of cysteine-containing amino acids, in particular N-acetylcysteine, rich in ergothioneine, S-carboxymethylcysteine, chelating means, in particular EDTA or Ethylenediamine, carotenoids, bioflavonoids, ubiquinone, idebenone, catalase, superoxide dismutase, lactoperoxidase, glutathione peroxidase, glutathione, benzylidene camphor, pidolate, lignans, melatonin, oryzanol, carnosine and its derivatives, GHK [INCL Tripeptide-1] and its salts and/or derivatives, Aldenine®[INCL: hydrolyzed wheat protein, hydrolyzed soy protein, Tripeptide-1], Preventhelia™ [INCL: diaminomaleonitrile-33] or Lipochroman-6 [INCL: �of metilmetakrilata], available from Lipotec, among others.

In a specific embodiment, the implementation of a means of inhibiting 5α-reductase, selected, for example, and without limitation, from the group formed by the following: extract Cinnamommum zeylanicum, Laminaria saccharina, Spiraea ulmaria, Nettle Root, Pygeum afn'canum, Avena Sativa, Serenoa repens, plant extracts of Arnica montana, Cinchona succirubra, Eugenia caryophyllata, Humulus lupulus, Hypericum perforatum, Mentha piperita, Rosmarinus officinalis, Salvia officinalis, Thymus vulgaricus extract of the genus Silybum extract, plant extract, which contain sapogenin and, in particular, an extract of plants of the genus Dioscorea, retinoids, in particular retinol, sulfur and its derivatives, zinc salts and, in particular, lactate, gluconate, pidolate, carboxylate, salicylate or cysteate zinc, chloride, selenium, vitamin B6, pyridoxine, capilarity, sarcosin, finasteride, dutasteride, isosteric, trosterud and their salts, among others.

Similarly, in another specific embodiment of the tool, inhibitory lysyl - and/or prolylhydroxylase selected, for example, and without limitation, from the group formed by the following: 2,4-diaminopyrimidine 3-oxide or 2,4-diamino-6-piperidinylidene 3-oxide, among others.

In another specific embodiment, the implementation of a means of stimulating defensin synthesis, selected, for example, and without limitation, from the group formed by the following: extracts or hydrolyzed Aloe Vera, Roast amaranth, Rehmannias radix, Arnica, Gardenia, Mor�praised some, orange, peach, pineapple, mint, gentian, hibiscus flower, leaf walnut, bottle gourd, peony, quinoa, boldo, rough bindweed, sunflower, elderberry, seaweed, hydrolysed maize, hydrolysed soy, hydrolyzed rice, valine and its isomers and derivatives, calcium and its salts, α-MSH and fragments contained in the amino acid sequence of α-MSH, vitamin a and its derivatives and precursors, vitamin D3 and its derivatives, zhasmonovaya acid, fumaric acid, malic acid, citric acid, ascorbic acid, lactic acid, acetic acid, adipic acid, tartaric acid, cinnamic acid, glutamic acid, succinic acid, inulin, Alkylglucoside, poly-D-glutamic acid, glycine, L-methionine, L-alanine, L-citrulline, laktoprotein, casein, lactoperoxidase, lysozyme, polyphenol, Alkylglucoside extract, Lactobacillus, extracts of fusobacteria or photosynthesise and asporogenic filamentous bacteria, acetyl-glutamyl-Oh-alanyl-isoleucine, acetyl-arginyl-phenylglycyl-phenylglycine or acetyl-arginyl-6-aminohexanoic-alanine, available from Lipotec, among others.

In another specific embodiment of the bactericidal and/or bacteriostatic agent, and/or antimicrobial, and/or a germicidal agent, and/or fungicidal agent and/or Fung�istoricheskoe means, and/or the inhibitor of pathogenic microorganisms are selected, for example and without limitation, from the group formed by the following: macrolides, pyranoside, calcium channel blockers, for example, and without limitation, Cinnarizine and diltiazem; hormones, for example, and without limitation, astral, its analogues or thyroxine and/or its salts, capriglione, imidazolidinethione, methyl 4-hydroxybenzoate [INCL: methylparaben], ethyl 4-hydroxybenzoate [INCL: ethylparaben,], propyl 4-hydroxybenzoate [INCL: propylparaben], butyl 4-hydroxybenzoate [INCL: butylparaben], isobutyl 4-hydroxybenzoate [INCL: isobutylparaben], 1,3-bis(gidroximetil)-5,5-dimethylimidazolidin-2,4-dione [INCL: the DMDM hydantoin], benzyl 4-hydroxybenzoate [INCL: benzylparaben], benzyl alcohol, digitoxose acid, benzoic acid, sorbic acid, salicylic acid, formic acid, propionic acid, 2-bromo-2-nitropropane-1,3-diol, 3-p-chlorophenoxy-1,2-propandiol [INCL: chlorphenesin], dichlorobenzyl alcohol, adpropinquaverant, benzalkonium chloride, absorbing the smell of fungicides such as zinc ricinoleate, cyclodextrins, benzene chloride, chlorhexidine, ethanol, propanol, 1,3-butanediol, 1,2-propylene glycol, undecylenic acid, digitoxose acid, N-methylmorpholine (MMA), isopropanol, methanol, 1,2-hexandiol, 1,2-octandiol, pentylindol, glycerinated, glycerine�rilat, glycerinated, benzoylperoxide, chlorhexidine gluconate, triclosan and its derivatives, Phenoxyethanol, terpinen-4-ol, α-terpineol, resorcinol, stiemycin, erythromycin, neomycin, clindamycin and its esters, tetracyclines, metronidazole, azelaic acid, tolnaftate, nystatin, clotrimazole, ketoconazole, derivatives of zinc, such as pyrithione zinc or tritional, zinc oxide and zinc undecylenate, pyroceramic, isothiazolinones, selenium, sulfur, benzenemethanol, boric acid, sodium borate, 6,6-dibrom-4,4-dichloro-2,2'-methylenediphenol [INCL: bremgarten], 5-bromo-5-nitro-1,3-dioxane, tosylchloramide sodium [INCL: chloramine T], chloracetamide, p-chloro-m-cresol, 2-benzyl-4-chlorphen [INCL: chlorphen], dimethyloxazolidine, dodecyldimethyl-2-phenoxyethylamine [INCL: domainbased], 7-atelecyclidae, hexetidine, glutaraldehyde, N-(4-chlorophenyl)-N-[4-chloro-3-(trifluoromethyl)phenyl]-urea [INCL: laplacean], 2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-[INCL: hinokitiol], isopropylethylene, salts of mercury, aluminum salts, nisin, Phenoxyethanol, o-phenylphenol, 3-heptyl-2-[(3-heptyl-4-Matip-3H-thiazol-2-Illidan)methyl]-4-methylthiazolidine [INCL: quaternium-73], silver chloride, sodium iodide, thymol, undecylenic acid, diethylenetriaminepentaacetic acid, ethylenediaminetetraacetic acid and ethylenediaminetetraacetate, lactoperoxidase, glucotor�Idasa, lactoferrin, alkylarylsulfonate, halogenated phenols, finaltotal and/or mixtures thereof, benzamidine, isothiazolines, phthalimide derivatives, pyridine derivatives, guanidine, quinolines, 1,2-dibrom-2,4-dicyanobutane, iodine-2-propylboronic, iodine, iodophors, peroxidase, 4-chloro-3,5-dimethylphenol, 2,2'-methylene-bis(6-bromo-4-chlorophenol), 3-methyl-4-(1-methylethyl)phenol, 3-(4-chlorphenoxy)-1,2-propandiol, 3,4,4'-trichlorocarbanilide (TTS), Cheminova essence, eugenol, farnesol, glycerylmonostearate, digitalmonkey, amides, N-alkylsalicylate acid, such as amide n-octylsilane acid or amide n-decimalizing acid, derivatives of halogenated xylene and cresol, such as p-chloro-meta-cresol or p-chloro-meta-xylene, extracts of Allium sativum, Calendula officinalis, Chamomilla recutita, Echinacea Purpura, Hyssopus Officinalis, Melaleuca alternifolia, or tea tree oil, essence of clove, menthol and mint essence, among others.

Similarly, in another specific embodiment of the agent, inhibiting NO-synthase, selected, for example, and without limitation, from the group formed by the following: extracts of plants of Vitis vinifera, Olea europaea or Gingko biloba, among others.

In a particular embodiment of the means for peeling and/or keratolytic agent and/or a means to exfoliate selected, for example, and without limitation, from the group formed by the following: g�of toxicity and their derivatives, β-hydroxy acids, in particular salicylic acid and its derivatives, or gentisic acid; α-hydroxy acids and their salts, such as glycolic acid, ammoniumnitrate, lactic acid, 2-hydroxyoctanoic acid, α-hydroxycaprylic acid, mandelic acid, citric acid, malic acid or tartaric acid; α - and β-hydroxybutyric acid; polyhydroxybutyrate, such as gluconic acid, glucuronic acid or sugar acid; keto acids such as pyruvic acid, Glyoxylic acid; pyrrolidinecarbonyl acid; cysteine acid and derivatives; aldobionic acid; azelaic acid and its derivatives, such as acelordellit; ascorbic acid and its derivatives, such as 6-O-palmitoylcarnitine acid, ascorbicacid, dialettologia acid, magnesium salt of ascorbic acid-2-phosphate (MAP), sodium salt of ascorbic acid-2-phosphate (NAP), ascorbyl tetraisopalmitate (VCIP); nicotinic acid, its esters and nicotinamide (also called vitamin B3 or vitamin PP); nordihydroguaiaretic acid; urea; oligopoly; cinnamic acid; derivatives of zhasmonovoi acid; hydroxystyrene such as resveratrol; extract, Saccarum officinarum; enzymes involved in desquamation or decomposition of corneodesmosomes, such as glycosidase, �matriptase the stratum corneum enzyme (SCCE) or other proteases, such as trypsin, chymotrypsin, strain, papain or bromelain; chelating agents such as ethylenediaminetetraacetic acid (EDTA), aminosulfonic compounds such as 4-(2-hydroxyethyl)piperazine-1-econsultancy acid (HEPES) or natriummetasilikaatti (TRILON®M, commercially available from BASF); derivatives of 2-oxothiazolidine-4-carboxylic acid (procysteine); derivatives of Sugars, such as O-octanoyl-6-D-maltose and N-acetylglucosamine; chestnut extract (Castanea sativa), such as commercially available from SILAB under the name Recoverine®[INCL: water (water) extract of seeds of Castanea Sativa]; the prickly pear extract (Opuntia ficus-indica), such as commercially available from SILAB as Exfolactive®[INCL: flower extract hydrolyzed Opuntia Ficus Indica]; or Phytosphingosine SLC®[INCL: salicylaldiminato], commercially available from Degussa/Evonik, PeeI-Moist [INCL: glycerin, papain, calcium Pantothenate, xanthan gum, capriglione, urea, packet magnesium, Ethylhexylglycerin, potassium lactate, serine, alanine, Proline, chloralkali, sodium citrate]; extract or combination of extracts of Saphora japonica, papaya, pineapple, large-fruited pumpkin or sweet potato, and/or mixtures thereof.

In another specific embodiment of the anti-inflammatory agent and/or analgesic agent selected, for example, and without limitation, from the group formed by the following: extract madecasses�Yes, Echinacea, oil of amaranth seed oil, sandalwood extract, peach tree leaves, Aloe vera, Arnica montana, Artemisia vulgaris, Asarum maximum, Calendula officinalis, Capsicum, Centipeda cunninghamii, Chamomilla recutita, Crinum asiaticum, Hamamelis virginiana, Harpagophytum procumbens, Hypericum perforatum, Lilium candidum, Malva sylvestris, Melaleuca alternifolia, Origanum majorana, Onganum vulgare, Prunus laurocerasus, Rosmahnus officialis, Salix alba, Silybum marianum, Tanacetum parthenium, Thymus vulgaris, Uncaria guianensis or Vaccinum myrtillus, mometasone furoate, prednisolone, nonsteroidal anti-inflammatory agents, including inhibitors of cyclooxygenase or lipoxygenase, benzydamine, acetylsalicylic acid, rosmarinic acid, ursolic acid, derivatives of DGL, α-bisabolol, azulene and analogues, seriesid, ruscogenin, escin, scholin, rutin, and analogues, hydrocortisone, clobetasol, dexamethasone, prednisone, paracetamol, aloxiprin, benorilate, holinsalitsilat, filamin, methyl salicylate, magnesium, spillet, salsalate, diclofenac, aceclofenac, acemetacin, bromfenac, etodolac, indomethacin, exaltation, proglumetacin, sulindac, tolmetin, ibuprofen, dexibuprofen, carprofen, fenbufen, fenoprofen, flurbiprofen, Ketoprofen, dexketoprofen, Ketorolac, loxoprofen, naproxen, miroprofen, oxaprozin, pranoprofen, tiaprofenic acid, suprofen, mefenamic acid, meclofenamate, meclofenamate acid, flufenamic acid, telenova acid, nabumetone, Hairdryer�lbutton, azapropazone, clofezone, kebuzone, Metamizole, mofebutazone, oxyphenbutazone, phenazone, sulfinpirazon, piroxicam, lornoxicam, meloxicam, tenoxicam, celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, valdecoxib, nimesulide, naproxcinod, flurocarbon or licofelone, omega-3 and omega-6 fatty acid, morphine, codeine, oxycodone, hydrocodone, diamorphine, pethidine, tramadol, buprenorphin, benzocaine, lidocaine, chloroprocaine, tetracaine, procaine, amitriptyline, carbamazepine, gabapentin, pregabalin, bisabolol, Neutrazen™ [INCL: water, butyleneglycol, dextran, palmitoleate-8], commercially available from Atrium Innovations/Unipex Group, Meliprene®[INCL; dextran, acetylglutamate-1], available from institut Europeen de Biologie Cellulaire/Unipex Group, SkinasensyI™ [INCL.: acetylnitrate-15] or AnasensyI™ [INCL: mannitol, ammoniumnitrate, caffeine, Hippocastanum extract (horse chestnut)], commercially available from Laboratoires Serobiologiques/Cognis, Calmosensine™ [INCL: acetylated-1], commercially available from Sederma, CoQ10 or alkylglycerol esters.

Furthermore, in another specific embodiment of the bleaching or depigmenting means selected, for example, and without limitation, from the group formed by the following: extracts of Achillea millefolium, Aloe vera, Aradirachta indica, Asmuna japonica, Autocarpus incisus, Bidens pilosa, Broussonetia papyrifera, Chlorella vulgahs, Cimicifuga racemosa, Emblica officinalis, Glycyirhiza glabra, Glycyrrhiza uralensis, Ilex purpurea, Ligusticum lucidu, Ligusticum wallichii, Mitracarpus scaber, Morinda citrifolia, Moms alba, Moms bombycis, Naringi crenulata, Prunus domesticus, radix Pseudostellariae, Rumex crispus, Rumex occidentalis, Sapindus mukurossi, Saxifragia sarmentosa, baicalensis Galericulate, Sedum sarmentosum Bunge, Stellaria medica, Triticum Vulgare, Uva ursi or Whitania somnifera, flavonoids, soy extract, lemon extract, orange extract, Ginkgo extract, cucumber extract, geranium extract, bearberry extract, carob extract, cinnamon extract, oregano extract, rosemary extract, clove flower extract, soluble licorice extract or an extract of the leaves of BlackBerry, lipochrome-6 [INCL: diethylmethoxyborane] or Chromabright™ [INCL: dimethylethoxysilane], available from Lipotec, Actiwhite™ LS9808 [INCL: water, glycerin, dilaurate sucrose, Polysorbate 20, extract, Pisum sativum (peas)] or high technologies®NF LS9410 [INCL: mannitol, arginine HCl, phenylalanine, disodium EDTA, sodium citrate, kojic acid, citric acid, yeast extract], available from Laboratoires Serobiologiques/Cognis, Lumiskin™ [INCL: Caprylic/Caproic triglyceride, diacetyl-Boldin], Melaclear™ [INCL: glycerin, water, diciottenni, gluconic acid, catiline, beta carotene], O. D. A. white™ [INCL: octadecenoic acid] or Etioline™ [INCL: glycerin, butyleneglycol extract of the leaves of Arctostaphylos uva ursi, the extract of Mitracarpus scaber], commercially available from Sederma, Sepiwhite™ MSH [INCL: underenrollment], commercially available from Seppic, Achromaxyl [INCL: water, extract of Brassica napus], available prodaje from Vinderice, Gigawhite™ [INCL: water, glycerin, extract, Malva sylvestris (mallow) extract, Mentha piperita leaf extract, Primula veris extract, Alchemilla vulgaris extract, Veronica officinalis extract, Melissa officinalis leaf extract, Achillea millefolium], Melawhite®[INCL: leukocyte extract, AHA] or Melfade®-J [INCL: water, extract of the leaves of Arctostaphylos uva-ursi, glycerin, magnesium ascorbyl phosphate], available from Pentapharm, Albatin®[INCL: aminoethylphosphonic acid, butyleneglycol, water], available from Exsymol, Tyrostat™-11 [INCL: water, glycerin, extract of Rumex occidentalis] or Melanostatine®-5 [INCL: dextran, nonapeptide-1], commercially available from Atrium Innovations, arbutin and its isomers, kojic acid and its derivatives, ascorbic acid and its derivatives, such as 6-D-palmitoylcarnitine acid, ascorbicacid, dialettologia acid, magnesium salt of ascorbic acid-2-phosphate (MAP), sodium salt of ascorbic acid-2-phosphate (NAP), ascorbicacid or ascorbyl tetraisopalmitate (VCIP); retinol and its derivatives, including tretinoin and isotretinoin, idebenone, hydroxybenzoic acid and its derivatives, Niacinamide, liquiritin, resorcinol and its derivatives, hydroquinone, α-tocopherol, γ-tocopherol, azelaic acid, acelordellit, resveratrol, linoleic acid, α-lipoic acid, dihydrolipoic acid, α-hydroxy acids, β-hydroxy acids, ellagic acid, �erolova acid, cinnamic acid, oleanolic acid, aloesin and its derivatives and/or inhibitors of semipretioase, for example, and without limitation, tryptase, inhibitors of trypsin or PAR-2, among others.

In another specific embodiment of the means of stimulating the synthesis of melanin, propagandise means and a means of self-Tanner and/or a means of stimulating the proliferation of melanocytes, selected, for example, and without limitation, from the group formed by the following: extracts of Citrus Aurantium Dulcis Fruit, Coleus forskohlii, Coleus Esquirolii, Coleus Scutellariodes, Coleus Xanthanthus, Ballota nigra, Ballota lanata, Ballota suavelens, Marrubium cylleneum, Cistus creticus, Amphiachyris amoena, Aster amulet, Otostegia fruticosa, Plectranthus barbatus, Halimium viscosum or Larix laricema, dihydroxyacetone and derivatives thereof, sugars, such as without limitation, erythrulose, melanin and its derivatives, including melanin polymers and melanin derivatives of low molecular weight that are soluble in water, Forskolin and derivatives thereof, including deacetylbaccatin and isotretoin, tyrosine and its derivatives, including acetyltyrosine, oleostearin, 3-aminosteroid and 3-nitrotyrosine, a copper salt such as CuCl2, carotenoids, canthaxanthin, polymers dihydroxyindoline acid, 3,4-dihydroxybenzoic acid, 3-amino-4-hydroxybenzoic acid, aloine, emodin, alizarin, DOPA, 4,5-dihydroxynaphthalene-2-sulfonic acid, 3-dimethylaminophenol �whether p-aminobenzoic acid, Melatime™ [INCL: acetyltributyl-40], commercially available from Lipotec, Heliostatine IS™ [INCL: Pisum Sativum extract], available from Vincience/ISP, Vegetan [INCL: dihydroxyacetone] or Vegetan Premium [INCL: dihydroxyacetone, melanin], available from Soliance, MelanoBronze [INCL: extract of Vitex Agnus Castus, acetyltyrosine], available from Mibelle Biochemistry, Melitane®[INCL: acetyl Hexapeptide-1], available from institut Europeen de Biologie CeHulaire/Unipex Innovations, Actibronze®[INCL: hydrolyzed Bapak wheat, acetyltyrosine, copper gluconate] or Instabronze®[INCL: dihydroxyacetone, tyrosine], commercially available from Alban Muller, Thalitan [INCL: hydrolyzed Algin, magnesium sulfate, manganese sulfate], available from CODIF, Tyrosilane®[INCL: methylselenocysteine], available from Exsymol, Tyr-Excel™ [INCL: oleostearin, oil seeds Luffa Cylindrica, oleic acid] or Tyr-OI [INCL: oleostearin, butyleneglycol, oleic acid], commercially available from Sederma/Croda, Bronzing S. F. [presumably INCL: butylpentyl], available from Infinitec Activos or Biotanning®(INCL: fruit extract hydrolyzed Citrus Aurantium Dulcis], commercially available from Silab, among others.

In a particular embodiment of the wrinkle and/or anti-aging agent selected, for example, and without limitation, from the group formed by the following: extracts of Vitis vinifera, Rosa canina, Curcuma longa, Iris pallida, Theobroma cacao, Ginkgo biloba, Leotopodium Alpinum or Dunaliella salina, Matrixyl®[INCL: polymethylpentene-4], Matrixyl 3000®(INCL: palmitostearate-7, palmitoylated], Essenskin™ (INCL: hydroxylation calcium], Renovage [INCL: teprenone] or Dermaxyl®[INCL: palmitoylated], commercially available from Sederma, Vialox®[INCL: Pentapeptide-3], Syn®-Ake®[INCL: ], Syn®-Coll (INCL: palmitoleate-5], Phytaluronate [INCL: gum carob tree (Ceratonia Siliqua)] or Preregen®(INCL: protein glycine soya (soybean), oxidoreductase], available from Pentapharm/DSM, Myoxinol™ [INCL: extract hydrolyzed Hibiscus Esculentus], Syniorage™ [INCL: acetylnitrate-11], Derrnican™ [INCL: acetylnitrate-9] or DN-AGE™ LS [INCL: extract of the leaves of Cassia Alata], available from Laboratoires Serobiologiques/Cognis, Algisum With®[INCL: methylsilanetriyl] or Hydroxyprolisilane CN®[INCL: ], available from Exsymol, Argireline®(INCL: acetyl Hexapeptide-8], SNAP-7 [INCL: acetylglutamate-4], SNAP-8 (INCL: acetolactate-3], LeuphasyI®[INCL: Pentapeptide-18], Aldenine®[INCL; hydrolyzed wheat protein, hydrolyzed soy protein, Tripeptide-1], Preventhelia™ [INCL: diaminomaleonitrile-33], Decorinyl™ [INCL: Tripeptide-10 citrulline], Trylagen®[INCL: enzyme Pseudoalteromonas extract, hydrolyzed wheat protein, hydrolyzed soy protein, Tripeptide-10 citrulline, Tripeptide-13, yeseryl ®[INCL: acetylnitrate-5], Peptide AC29 [INCL: acetyltributyl-30 citrulline], Lipochroman-6 [INCL: diethylmethoxyborane], Chromabright™ [INCL: dimethylethoxysilane], Antarcticine®[INCL: enzyme extract of Pseudoalteromonas], Vilastene™ [INCL: lysine HCl, lecithin, Tripeptide-10 citrulline], dGlyage™ [INCL: lysine HCl, lecithin, Tripeptide-9 citrulline], acetyl-arginyl-phenylglycyl-tryptophyl-phenylglycine, acetyl-arginyl-phenylglycyl-valyl-glycine or acetyl-arginyl-phenylglycyl-valyl-phenylglycine, Inyline™ [INCL: acetyl Hexapeptide-30], available from Lipotec, Kollaren®[INCL: Tripeptide-1, dextran], available from Institut Europeen de Biologie Cellulaire, Collaxyl®IS [INCL: Hexapeptide-9], Laminixyl IS™ [INCL: heptapeptide], Orsirtine™ GL [INCL: extract Oryza Sativa (rice)], D Orientine™ IS [INCL.: seed extract, Phoenix Dactylifera (date)], Phytoquintescine™ (INCL: extract of wheat odnosemyanka (Triticum Monococcum)] or Quintescine™ IS [INCL: dipeptide-4], available from Vincience/ISP, BONT-L-Peptide [INCL: palmitoleate-19], available from Infinitec Activos, Deepaline™ PVB [INCL: Palmitoyl, hydrolyzed wheat protein] or Sepilift®DPHP [INCL: dipalmitoylphosphatidyl], commercially available from Seppic, Gatuline®Expression [INCL: extract of Acmella oleracea], Gatuline®In-Tense [INCL: flower extract Spilanthes Acmella] or Gatuline®Age Defense 2 [INCL: seed extract, Juglans Regia (walnut)], commercially available from Gattefosse, Thalassine™ [INCL: algae extract], available on� Biotechmarine, ChroNOiine™ [INCL: caprolactamate-3] or Thymulen-4 [INCL: acetylnitrate-2], commercially available from Atrium Innovations/Unipex Group, EquiStat [INCL: fruit extract Pyrus Malus extract, glycine soya seeds] or Juvenesce [INCL: ethoxydiglycol and Caprylic triglyceride, retinol, ursolic acid, phytonadione, ilomastat], available from Coletica, Ameliox [INCL: carnosine, tocopherol, Silybum Marianum fruit extract] or PhytoCellTec Malus Domestica [INCL: cell culture Malus Domestica fruit], available from Mibelle Biochemistry, Bioxilift [INCL: Pimpinella Anisum extract] or SMS Anti-Wrinkle®[INCL: extract of seeds of Annona Squamosa], commercially available from Silab, a blocker of Ca2+channels, for example, and without limitation, alvein, salts of manganese or magnesium, some secondary or tertiary amines, retinol and its derivatives, resveratrol, idebenone, coenzyme Q10 and its derivatives, Boswellia acid and its derivatives, GHK and its derivatives and/or salts, carnosine and its derivatives, DNA repair enzymes, for example, and without limitation, photolyase or endonuclease V T4 or blockers of chloride channels, among others.

In a particular embodiment of the lipolytic agent, or a means of stimulating lipolysis, venotonic agent and/or anti-cellulite remedy is selected, for example, and without limitation, from the group formed by the following: extracts of Bupleurum Chinensis, Cecropia Obtusifolia, Celosia Cristata, Centella Asiatica, Chenopodium Quinoa, Chrysanthellum Indicum, Ctrus Aurantium Amara, Coffea Arabica, Coleus Forskohlif, Commiphora Myrrha, Chthmum Maritimum, Eugenia Caryophyllus, Ginkgo Biloba, Hedera Helix (ivy extract common), Hibiscus Sabdaiiffa, Ilex Paraguariensis, Laminaria Digitata, Nelumbium Speciosum, Pauilinia Cupana, Peumus Boldus, Phyllacantha Fibrosa, Prunella Vulgaris, Prunus Amygdalus Dulcis, Ruscus Aculeatus (butcher's broom extract), Sambucus Nigra, Spirulina Platensis Algae, Uncaria Tomentosa or Verbena Officinalis, dihydromyricetin, coenzyme a, lipase, glaucine, esculin, visnadin, Regu®-Shape [INCL: samaritana linoleic acid, lecithin, glycerin, Polysorbate 80], available from Pentapharm/DSM, UCPeptideTM V [INCL: Pentapeptide] or AT PeptideTM IS [INCL: Tripeptide-3], commercially available from Vincience/ISP, Liporeductyl®[INCL: caffeine, an extract of the root of butcher's broom (Ruscus Aculeatus), tea-hydroiodide, carnitine, ivy extract (Hedera Helix), escin, Tripeptide-1], available from Lipotec, Adiposlim [INCL: sorbitanoleat, laurelbrook], available from SiEPPIC, caffeine, carnitine, escin and/or triethanolamine, among others.

In a particular embodiment of the means of stimulating the synthesis of heat shock proteins, are selected, for example and without limitation, from the group formed by the following: extracts of Opuntia ficus indica, Salix alba, Lupinus spp., Secale cereale, extracts of red algae from the genus Porphyra, extracts of crustaceans of the genus Artemia, seed oil, jojoba oil, extracts of grape seeds, extracts of green tea, geranylgeranylation, celastrol, zinc and its salts, 2-cyclopenten-1-he, proteasome inhibitors, e.g.�, and without limitation, bortezomib; prostaglandins and their derivatives, hydroxylamine and its derivatives, for example, and without limitation, bioglobal; the Halcon and its derivatives, hyperosmotic agents, for example, and without limitation, sorbitol and its derivatives, mannitol and its derivatives or glycerol and its derivatives, isosorbide, urea or salicylic acid and its derivatives, among others, or mixtures thereof.

In a particular embodiment of the means of inducing hair growth or inhibiting hair loss, selected, for example, and without limitation, from the group formed by the following: extracts of Tussilago farfara, or Achillea millefolium, esters of nicotinic acid, such as C3-C8alkylsulfonate, such as methyl or exillerating, benzylsuccinic or tocopherylacetate; Biotin, means of inhibiting 5α-reductase, anti-inflammatories, retinoids, for example, and without limitation, pretransitional acid or tretinoin, isotretinoin, retinol or vitamin a, and derivatives thereof, such as acetate, palmitate, propionate, matricine, etretinate and zinc salt of all-TRANS retinoic acid; antibacterial agents, calcium channel blockers, for example, and without limitation, Cinnarizine and diltiazem; hormones, for example, and without limitation, estriol, its analogues or thyroxine, its analogs and/or salts; �antiandrogen funds for example, and without limitation, oxendolone, spironolactone, or diethylstilbestrol; protivoradikulitnye funds esterified oligosaccharides, for example, and without limitation, those described in documents EP 0211610 and EP 0064012; derivatives hexasaccharide acids, for example, and without limitation, glucoseamine acid or those described in document EP 0375388; glucosidase inhibitors, for example, and without limitation, D-glucaro-1,5-lactam or those described in document EP 0334586; inhibitors of glycosaminoglycans and proteoglycans, for example, and without limitation, L-galactono-1,4-lactone or those described in document EP 0277428; tyrosine kinase inhibitors, for example, and without limitation, 1-amido-1-cyano(3,4-dihydroxyphenyl)ethylene or those described in document EP 0403238, diazoxide, for example, and without limitation, 7-(acetylthio)-4',5'-dihydrospiro[androst-4-ene-17,2'-(3H)furan]-3-one, 1,1-dioxide 3-methyl-7-chloro[2H]-1,2,4-benzotiadiazina or spirooxazine; phospholipids, for example, and without limitation, lecithin; salicylic acid and its derivatives, hydroxycarbonate or ketocarboxylic acids and their esters, lactones and their salts; anthralin, AKOS-5,8,11-triene acids and their esters or amides, among other things, Minoxidil and its derivatives, or mixtures thereof.

In another specific embodiment, the implementation of a means of inhibiting or retarding the growth of body hair, selected�, for example, and without limitation, from the group formed by the following: activin or activin agonists, flavonoids, such as quercetin, curcumin, galangin, fisetin, myricetin, apigenin; propylgallate, nordihydroguaiaretic acid, caffeic acid, tyrosine kinase inhibitors, such as levendusky, erbstein, tyrphostin, the benzoquinone-animatedseries And, thiazolidinediones, phenazocine, 2,3-dihydro-2-thioxo-1H-indole-3-alkane acid, phenothiazine derivatives, such as thioridazine; sphingosine and derivatives thereof, STS and its derivatives, glycyrrhetic acid, laurelissocoollike, Decelerine™ [INCL: laurelissocoollike, enzyme extract, Pseudoalteromonas], available from Lipotec or inhibitors semipretioase, trypsin and/or mixtures thereof.

In a particular embodiment of the cosmetic and/or absorbent and/or masking body odor deodorant and/or means-antiperspirant, aromatic substance and/or aromatic oils are selected, for example and without limitation, from the group formed by the following: complex zinc salt of ricinoleic acid, storax, derivatives of abietic acid, essence of sage, essence chamomile, essence of cloves, essence of lemon, essence of peppermint, essence of the leaves of cinnamon, essence of lime blossom, essence of juniper berry, essence of vetiver, essence incense�, the galbanum essence, essence labdanum, essence of lavender, essence of peppermint, citrus bergamot, dihydromyrcenol, lilial, lyral, citronellol, essence of lemon, Mandarin essence, orange essence, essence of lavender, nutmeg, essence of geranium Bourbon, anise seed, coriander, cumin, juniper, extracts of iris, lilies, roses, Jasmine, bitter orange flowers; benzoylacetate, p-tert-butylcyclohexylamine, minalrestat, fenilatilamin, ethylmethylketone, lisalivingood, benzoylformate, arylcyclohexylamines, styrelseledamot, benzalkonium, benzylation ether, linear alkanes with 8-18 carbon atoms, citral, ricinolein acid, citronellal, citronellaldehyde, collateralized, hydroxycitronellal, bourgeonal, ionone, metilacrylate, anethole, eugenol, isoeugenol, geraniol, linalool, terpineol, generationy alcohol, α-hexylcinnamaldehyde, geraniol, benzylacetone, collateralized, Boisambrene Forte®ambroxan, indole, Gedeon, sandales, cyclopentyl, β-Damasco, allylamines, dihydromyrcenol, phenoxyethylamine, cyclohexylglycine, Vertofix Coeur, Iso-E-Super, Fixolide NP, averil, phenylacetic acid, geranyl acetate, roumillat, erotic, format, active tightens pores products such as aluminium chloride, aluminium chloride, dihydrochloride aluminum, sesquichloride aluminum�I, hydroxyalkanoate aluminum, charterted aluminum, trichloride of aluminum and zirconium, tetrachloride of aluminum and zirconium, pentachloride of aluminum and zirconium and/or mixtures thereof.

In a particular embodiment of the antioxidant is selected, for example, and without limitation, from the group formed by the following: butyl hydroxytoluene (BHT), trouble soothing (BHA), tert-butylhydroquinone (TBHQ), 2,6-di-tert-butyl-4-METHYLPHENOL, esters of Gallic acid, such as propylgallate, probucol, polyphenols, ascorbic acid and its salts, enzymes such as catalase, superoxide dismutase and peroxidase; citric acid, citrate, esters of monoglycerides, metabisulfate of calcium, lactic acid, malic acid, succinic acid, tartaric acid, vitamin a or β-carotene, vitamins E and C, Tocopherols, such as vitamin E acetate, esters of ascorbic acid such as ascorbyl palmitate and ascorbicacid, zinc, copper, mannitol, reduced glutathione, carotenoids, such as cryptoxanthin, astaxanthin, and lycopene; cysteine, uric acid, carnitine, taurine, tyrosine, lutein, zeaxanthin, and N-acetyl-cysteine, carnosine, γ-glutamylcysteine, quercetin, lactoferrin, dihydrolipoic acid, catechins of tea, remineralised and its derivatives, bisulfate, a metabisulfite and a sulfite-sodium, chromane, chromenes and analogs thereof, Lipochroman-6 [ICL: diethylmethoxyborane], chelating means of metals, such as EDTA, sorbitol, phosphoric acid or dGlyage™ [INCL: lysine HCl, lecithin, Tripeptide-9 citrulline]; Ginkgo Biloba extract, plant extracts, such as sage, pomegranate, rosemary, oregano, ginger, marjoram, cranberry, grape, tomato, green tea or black tea; extract oleoresins, extracts of plants that contain phenols, such as vanillin, ellagic acid and resveratrol; tertiary butylhydroquinone or mixtures thereof, salts of metals with a valence of 2, such as selenium, cadmium, vanadium or zinc; α-lipoic acid, coenzyme Q, idebenone or its derivatives.

In a particular embodiment of the means inhibiting the enzymes the collapse of sweat, selected, for example, and without limitation, from the group formed by the following: trialkylsilyl, such as trimethylsilyl, tripropyltin, triisopropylsilyl, tributyltin or triethylcitrate; anotherinsulin or phosphate, cholesterol, campesterol, stigmasterol and sitosterol; dicarboxylic acids and their esters, such as glutaric acid, monoacylglycerol, diacylglycerol, adipic acid, monetisation, diethylacetal; malonic acid and diethylmalonate, hydroxycarbonate acids and their esters, such as malic acid, tartaric acid or titillate, glycinate zinc and/or mixtures thereof.

In another specific embodiment implemented�I means, capable of filtering UV rays, selected, for example, and without limitation, from the group formed by the following: organic or mineral photoprotective agents active against A and/or UV rays, such as substituted benzotriazoles, substituted diphenylacetate, organic complexes of Nickel, umbelliferone, rocanova acid, derivatives of biphenyl, stilbene, 3-benzylidene camphor and its derivatives, such as 3-(4-methylbenzylidene)camphor; derivatives of 4-aminobenzoic acid, 2-ethylhexyl 4-(dimethylamino)benzoate, 2-octyl 4-(dimethylamino)benzoate and amyl 4-(dimethylamino)benzoate; esters of cinnamic acid such as 2-ethylhexyl 4-methoxycinnamate or , propyl 4-methoxycinnamate, isoamyl 4-methoxycinnamate, 2-ethylhexyl (octocrylene) 2-cyano-3,3-phenylcinnamic; esters of salicylic acid, such as 2-ethylhexylacrylate, 4-isopropylbenzylamine, homogentisate; benzophenone derivatives such as 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone; esters of benzopyranones acids, such as di-2-ethylhexyl 4-methoxybenzylamine; triazine derivatives such as 2,4,6-Tianjin, p-Carbo-2'-ethyl-1'-hexyloxy-1,3,5-triazine, ochiltree or deactivatefeature; propane-1,3-dione, such �AK 1-(4-tert-butylphenyl)-3-(4'-methoxyphenyl)propane-1,3-dione; derivatives cetorelli(5.2.1.0)Dean; 2-phenylbenzimidazol-5-sulfonic acid; derivatives benzopinacolone acids such as 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its CDIS; 4-(2-oxo-3-barelydigital)mixture of Benzenesulfonic acid, derivatives benzoylamino, such as benzoylmethyl 2-methyl-5-(2-oxo-3-borrelidin)sulfonic acid such as 1-(4'-tert-butylphenyl)-3-(4'-methoxyphenyl)propane-1,3-dione, 4-tert-butyl-4'-methoxydibenzoylmethane, 1-phenyl-3-(4'-isopropylphenyl)-propane-1,3-dione, the compounds of enamine, anthranilate, silicones, derivatives of benzimidazole, imidazoline, benzoyl derivatives, Chromabright™ [INCL: dimethylethoxysilane] or Preventhelia™ [INCL: diaminomaleonitrile-33], both commercially available from Lipotec, metal oxides such as zinc oxide, titanium, iron, zirconium, silicon, manganese, aluminum and cerium; silicates, talc, barium sulfate, zinc stearate, carbon nanotubes and/or mixtures thereof.

Furthermore, in another specific embodiment, the implementation of a means of stimulating or regulating the differentiation of keratinocytes, selected, for example, and without limitation, from the group formed by the following: minerals such as calcium, retinoids such as retinol or tretinoin, analogues of vitamin D3, such as calcitriol, calcipotriol or tacalcitol, extract of Lupin (Lupinus albus), such as available in �rodaje from SILAB under the name Structurin ®[INCL: hydrolyzed lupine protein], β-sitosterolemia, such as commercially available from Vincience/ISP under the name Phytocohesine PSP®[INCL: beta sitosterolemia sodium], corn extract (Zea Mays), such as commercially available from Solabia under the name Phytovityi With®[INCL: water (water), extract of Zea Mays], glycoconjugates Helix Aspersa Muller and/or mixtures thereof.

Similarly, in another specific embodiment of the muscle relaxant, agent, inhibiting muscle contraction, a means of inhibiting the clustering of the acetylcholine receptor and/or anticholinergic agent selected, for example, and without limitation, from the group formed by the following: extracts of Atropa belladonna, Hyoscyamus niger, Mandragora officinarum, Chondodendron tomentosum, plants of the genus Brugmansia or of the genus Datura, Clostridium botulinum toxin, peptides derived from the protein SNAP-25 or Inyline™ [INCL: acetyl Hexapeptide-30], available from Lipotec, baclofen, carbidopa, levodopa, bromocriptine, chlorphenesin, chlorzoxazone, donepezil, mephenoxalone, reserpine, tetrabenazine, dantrolene, thiocolchicoside, tizanidine, clonidine, procyclidine, glycopyrrolate, atropine, hyoscyamine, this drug, scopolamine, promethazine, diphenhydramine, dimenhydrinate, dicyclomine, cyclobenzaprine, orphenadrine, flavoxate, cyclopentolate, ipratropium, oxybutynin, pirenzepine, Tiotropium, trihexyphenidyl, tolterodine, Tropicamide, solifenacin, darifenacin, m�Beveren, trimetaphan, atracurium, cisatracurium, doxacurium, pozadini, metocurine, mivacurium, pancuronium, pipecuronium, rapacuronium, tubocurarine, dimethyltubocurarine, rocuronium, vecuronium, suxamethonium, pre 18-methoxycoronaridine, carisoprodol, fearbut, meprobamate, Methocarbamol, phenprobamate, Tiamat, anticonvulsant agents such as levetiracetam, stiripentol, phenobarbital, methylphenobarbital, pentobarbital, metharbital, barbexaclone, pyrimido, carbamazepine, oxcarbazepine, benzodiazepines, for example, and without limitation, clonazepam, cloxazolam, clorazepate, diazepam; flutoprazepam, lorazepam, midazolam, nitrazepam, nimetazepam, phenazepam, temazepam, tetrazepam or clobazam, among others.

In another specific embodiment of the active ingredient is an insect repellent and is selected, for example, and without limitation, from the group formed by the following: DEET (N,N-diethyl-meta-toluamide), ethylhexanediol, dihydronaphthalene or a mixture of stereoisomers dihydronaphthalene, 3-methylbutanal, 2-methylbutanal, substituted hydroxy or aminomethylphenol; valeraldehyde and TRANS-pentenal, fenvalerate, esfenvalerate, 1S,3S,4S,6R-Karen-3,4-diol, DIPROPYLENE-2,5-dicarboxylate, polytetrafluoroethylene, polivinilhlorid and vinylidenechloride, dimethylsiloxane, polyvinyl chloride, vinylidenechloride, phthalic acid, Dima�elftal, dibutyl phthalate, terephthalate, Indalo (butyl-3,3-dihydro-2,2-dimethyl-4-oxo-2H-PYRAN-6-carboxylate), turmeric (Curcuma longa), bicyclic iridoid lactones, iridomyrmecin pheromones, sulfur, Epsom salts (hydrated calcium sulfate), pyrethrum or Dalmatian chrysanthemum (Chrysanthemum cinerariaefolium), lemon grass (Cymbopogon nardus), minalrestat, 1-limonene, cineol, eugenol, eugeniasea, piperidine, such as picaridin or bayrepel (2-(2-hydroxyethyl)-1-methylpropyloxy ester 1-piperidinecarbonitrile acid) and its stereoisomers, 1-(3-cyclohexene-1-yl-carbonyl)-2-demerol and its stereoisomers, or ethylbutylamine, 1-(3-cyclohexene-1-yl-carbonyl)piperidine, soridormi, 2,3,4,5-bis(2-bugilin)tetrahydrofurfural, glycolipoprotein, N-butylacetamide, dibutyltin, di-n-butylamine, dimethylcarbonate (endo, endo)-dimethyl-bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate, 2-ethyl-2-butyl-1,3-PROPANEDIOL, 2-ethyl-1,3-hexandiol, propylitization, 2-phenylcyclohexanol, normal-propyl N,N-diethylacrylamide, butylacetoacetate, 2-ethyl-1,3-hexanediol, N,N-diethylbenzamide, p-methane-3,8-diol, N,N-diethylaniline, soulgorger, ethyl-3-[N-n-butyl-N-acetyl] aminopropionic, diisopropylamide, alpha bisabol, benzyl alcohol, N,N-diethylformamide, vitamin E, the lactone of 3-acetyl-2-(2,6-dimethyl-5-heptenyl)oxazolidin (2-hydroxide�illlogical)acetic acid, tefluthrin, permethrin, cypermethrin, cyhalothrin, lambda-cyhalothrin, bifenthrin, deltamethrin, oil achiote or annato (Bixa orellana), leaves and fruits of lemon (Citrus medica), oil of bitter almonds, anise oil, Basil oil, Bay oil, caraway seeds, cardamom oil, cedar oil, celery oil, chamomile oil, oil curly mint, cinnamon oil, citronella oil, clove oil, oil of cilantro, Kumanovo oil, dill oil, eucalyptus oil, fennel oil, ginger oil, grape seed oil, lemon oil, peppermint oil, parsley oil, oil of Japanese Catnip, peppermint oil, rose oil, mint oil (menthol), sweet orange oil, coconut oil, cedar oil, geranoil, geranium oil, thyme oil and oil of turmeric.

It was previously described that the colloids used in the first stage of the method of this invention, were hydrophilic, and to dissolve, the solvent should also be hydrophilic, such as water or an aqueous solution, which was also previously described. The active ingredient or ingredients must be suspended in this solvent, as described in step (a) of the method of the present invention. However, the present invention is not limited to lipophilic active ingredients suspended in a hydrophilic solvent. In a specific embodiment, the OS�span in the case of hydrophilic active ingredients active ingredient emulsified in water in oil emulsion, emulsion water-in-oil and suspended in step a). In another specific embodiment, the implementation of this emulsion water-in-oil, containing the active ingredient, which contains, in turn, in solid lipid nanoparticles, SLN, or in nanostructured lipid carrier, NLC, which is suspended in step (a) of the method of the present invention.

The second aspect of this invention relates to fiber and/or textile material obtained according to the method of the present invention. In the present invention under textile materials understand woven fabric, non-woven materials, clothing, and medical devices. Among the preferred textile materials woven fabrics, non-woven materials, clothing, and medical devices are bandages, gauze, t-shirts, socks, tights, underwear, girdles, gloves, diapers, sanitary napkins, dressings, bedspreads, wipes, hydrogels, adhesive patches, neagative patches, micro-electric patches and/or face masks

The third aspect of this invention relates to the use of fibers and/or textile materials obtained according to the method of the present invention, for the treatment and/or care of skin, hair and/or scalp. Preferably, treatment and/or care of skin, hair and/or scalp selected from the group formed�th following; treatment and/or prevention of skin aging, healing of the skin and/or scalp, dermatological treatment of skin diseases, treatment and/or prevention of cellulite, tan skin, brightening or whitening of the skin and treatment and/or prevention of hair loss.

In the context of this invention the term "aging" refers to the changes of the skin with age (aging) or because of exposure to the sun (photoaging) or medium environment, such as tobacco Smoking, extreme climatic conditions of cold or wind, chemical pollutants or pollution, and includes all the external visible changes, as well as those that can be detected by touch, for example, and without limitation, the development of inhomogeneities in the structure of the skin, such as wrinkles, fine lines, deep wrinkles, irregularities or roughness, increase in the size of pores, loss of elasticity, the loss of density, loss of smoothness, loss of the ability to recover after deformation, sagging skin such as sagging cheeks, the appearance of bags under the eyes or the appearance of a double chin, among other things, change the color of the skin, such as nevi, redness, bags under the eyes, the appearance of hyperpigmented areas such as age spots or freckles among others, anomalous differents�orchestration, hyperkeratinization, elastosis, keratosis, hair loss, skin type, orange skin, loss of collagen structure and other histological changes of the stratum corneum, dermis, epidermis, vascular system (for example, the appearance of spider veins or telangiectasias) or of the tissues adjacent to the skin, among others.

The following specific examples provided in this paper serve to illustrate the nature of this invention. These examples are included merely for illustrative purposes and should not be construed as limitations of this invention, as stated in this document.

DESCRIPTION of FIGURES

Figure 1: Figure 1 shows photographs of scanning electron microscopy for the treated polyamide fabric, example 6, which were associated microcapsules of example 4 by the use of plyaski. Part a) is an untreated polyamide, part b) polyamide after 0 washes, part C) polyamide after 5 washings.

EXAMPLES

General methods

All reagents and solvents are of a quality suitable for the synthesis and used without any additional processing.

EXAMPLE 1

Getting cationizing microcapsules containing Chromabright™ polyquaternium-16

The carboxymethyl cellulose was dissolved in water (phase b). Further, gelatin was dissolved in water (phase A) with stirring,� within 15 minutes and the phase And brought to the boiling point. Bath set at 75°C and phase b was added to phase A and was convinced that the temperature did not fall below 60°C and that the pH of the mixture ranged from 5 to 5.5. The components of phase C were added under maximum agitation and a temperature above 60°C. the pH was lowered very slowly using the components of phase D until he left him at approximately 4,43. Was stirred for 30 min and pH was measured (4,42). The mixture was allowed to cool, with stirring for 2 hours and after half of the process, pH was measured (4,55) and brought it to 4,44 using the components of phase D. the pH was raised to 7.5 by adding the components of phase E, and then added the components of phase F, divorced Poperechnaya agent, and stirred overnight. The next day was G added as the cationic polymer and stirred for 3 hours.

INGREDIENT (INCL Item)Per cent BY WEIGHT
AndGELATIN (150 IN 30/40)2,4
AndWATER (WATER)q.s.p.100
InCELLULOSE GUM0,6
In WATER (WATER)35,1
BETA-CAROTENE1,00
DIMETHYLETHOXYSILANE1,00
MINERAL OIL (liquid PARAFFIN OIL)8,00
DCITRIC ACID0,15
DWATER (WATER)0,35
ESODIUM HYDROXIDE0,09
EWATER (WATER)0,21
FGLUTARAL0,50
FWATER (WATER)0,50
GPOLYQUATERNIUM-1615,0

EXAMPLE 2

Getting cationizing microcapsules containing Inyline™ polyquaternium-16

Initially, Inyline™ [INCL: acetyl Hexapeptide-30] was dissolved in in�de and alcohol (phase C). Phase slowly added to phase D with stirring. These two phases together was added to soybean oil (phase E). After that, the carboxymethyl cellulose was dissolved in water (phase b). Further, gelatin was dissolved in water (phase A) and stirred for 15 minutes and the phase And brought to the boiling point. Bath set at 75°C and phase b was added to phase A and was convinced that the temperature did not fall below 60°C and that the pH of the mixture ranged from 5 to 5.5. The mixture of phases C, D and E were added under maximum stirring and at a temperature above 60°C. the pH was lowered by using components from phase F very slowly, until he left him at approximately 4,43. Was stirred for 30 min and pH was measured (4,39). The mixture was allowed to cool to room temperature with stirring. the pH was raised to 7 by adding the components of phase G, and then added the components of phase H, diluted Poperechnaya agent, and stirred overnight. The next day I added as the cationic polymer and stirred for 3 hours.

INGREDIENT (INCL Item)Per cent BY WEIGHT
AndGELATIN (150 IN 30/40)2,4
AndWATER (WATER) 30,10
InCELLULOSE GUM0,6
InWATER (WATER)30,10
Acetyl Hexapeptide-300,00004
THE ALCOHOL DENAT.0,007
CWATER (WATER)q.s.p.100
DDIOCTYLSULFOSUCCINATE0,013
DEZOTERIKOVA ACID0,08
ESOYBEAN OIL (GLYCINE SOYA)10,00
FCITRIC ACID0,15
FWATER (WATER)0,35
GSODIUM HYDROXIDE0,09
GWATER (WATER)/td> 0,21
HGLUTARAL0,50
HWATER (WATER)0,50
IPOLYQUATERNIUM-1615,0

EXAMPLE 3

Getting cationizing microcapsules containing Argireline®with polyquaternium-16

Microcapsules Argireline®[INCL: acetyl Hexapeptide-3] was obtained as in example 2, but replacing Inyline™ [INCL: acetyl Hexapeptide-30] on Argireline®[INCL: acetyl Hexapeptide-3].

/table>

EXAMPLE 4

Getting cationizing microcapsules containing Antarcticine®and vitamin E acetate with polyquaternium-16

Microcapsules were obtained in the same way as in example 1, replacing Chromabright™ Antarcticine®[INCL: enzyme extract Pseudoalterornonas] and vitamin E acetate.

INGREDIENT (INCL Item)Per cent BY WEIGHT
AndGELATIN (150 IN 30/40)2,4
AndWATER (WATER)30,10
InCELLULOSE GUM0,6
InWATER (WATER)30,10
Acetyl Hexapeptide-3 A 0.00025
THE ALCOHOL DENAT.0,007
WATER (WATER)q.s.p.100
DDIOCTYL SULFOSUCCINATE0,013
DEZOTERIKOVA ACID0,08
ESOYBEAN OIL (GLYCINE SOYA)10,00
FCITRIC ACID0,15
FWATER (WATER)0,35
GSODIUM HYDROXIDE0,09
GWATER (WATER)0,21
NGLUTARAL0,50
NWATER (WATER)0,50
IPOLYQUATERNIUM-1615,0
INGREDIENT (INCL Item)Per cent BY WEIGHT
AndGELATIN (150 IN 30/40)2,4
AndPHENOXYETHANOL0,835
AndPROPANDIOL4,175
AndWATER (WATER)q.s.p.100
InCELLULOSE GUM0,6
InWATER (WATER)30,00
ENZYME EXTRACT of PSEUDOALTEROMONAS0,40
TOCOPHERYLACETATE3,50
SOYBEAN OIL (GLYCINE SOYA)6,50
DCITRIC ACID0,15
DWATER (WATER)1,00
ESODIUM HYDROXIDE0,10
EWATER (WATER)10,00
FGLUTARAL0,50
FWATER (WATER)0,50
GPOLYQUATERNIUM-1615,0

EXAMPLE 5

Textile material containing Antarcticine®and vitamin E acetate, and determining the quantity of vitamin E acetate after a few washes.

Linked microcapsules of example 4. The connection or binding of the microcapsules of example 4 with textile materials was performed using exhaustion of the bath. Textiles were hung out to dry after a bath according to standard UNE-EN ISO 6330.

To test sternoptychidae of microcapsules associated with described basetexture materials the latter was treated with solutions of detergent with stirring in accordance with ISO I05 CO6. Textiles were hung out to dry according to standard UNE-EN ISO 6330 after each washing. The determination of the number of microcapsules that are connected with the textile material, was performed by determining HPLC (Column: Nucleosil C18 100A, 5 μm, 250×4.6 mm; mobile phase: water and methanol, flow 0.7 ml/min, detection at 290 nm) amount of the active ingredient present in the textile material. Amount of the active ingredient associated with the textile material after the bath and after a number of washings was determined after extraction of vitamin E acetate textile material by treatment with ultrasound for 10 minutes. External phase was filtered (0.45 µm) and analyzed with a detector HPLC-UV/visible. Percentage of vitamin E acetate present in the textile materials after five washings, averaged 66% in relation to the percentage of vitamin E that is associated initially.

EXAMPLE 6

Textile material containing Antarcticine®and vitamin E acetate, and determining the quantity of vitamin E acetate after a few washes.

Linked cationic microcapsules of example 4. The connection or binding of the microcapsules of example 4 with textile materials was performed by way of plyaski pressure 1 bar, linking at 150°C for 2 minutes, 914 g of the microcapsules of example 4 per 1000 liters of bath). The textile material was dried at 150°C for 2 minutes.

To test sternoptychidae of microcapsules associated with the above-described textile materials, the latter was treated with solutions of detergent with stirring in accordance with ISO I05 CO6. Textiles were hung out to dry according to standard UNE-EN ISO 6330 after each washing. The determination of the number of microcapsules that are connected with the textile material, was performed by determining HPLC (column: Nucleosil C18 100A, 5 μm, 250×4.6 mm; mobile phase: water and methanol, flow 0.7 ml/min, detection at 290 nm) amount of the active ingredient present in the textile material. Amount of the active ingredient associated with the textile material after the bath and after a number of washings was determined after extraction of vitamin E acetate textile material by treatment with ultrasound for 10 minutes. External phase was filtered (0.45 µm) and analyzed with a detector HPLC-UV/visible. Percentage of the presence of vitamin E acetate in relation to the percentage of vitamin E that is associated initially shown in the table below.

% vitamin EPaul�amide Cotton
0 washes10036
1 wash8925
5 washes3627
10 washes3012
20 washings16

The presence of microcapsules, connected with the textile material was verified by scanning electron microscopy (see Fig.1). Different textile materials were dehydrated in dehydrator for 48 hours, and was covered with a multilayer coating of small particles of gold (200 Å). Used microscope was a FEI Quanta-200, FEI Company, North America, at 10 kV, owned by scientific-technical services of the University of Barcelona.

1. A method of processing fibers and/or textile materials, which comprises the following steps:
(a) the dissolution of two hydrophilic colloids in the solvent in which they are soluble, and adding at least one active ingredient to form a suspension of the active ingredient in this solution,
(b) adjusting pH and/�whether the breeding of previous suspensions to call coacervation colloids and their deposition on the active ingredient, which is encapsulated,
c) increasing the pH of the slurry and adding Poperechnaya means for solidification of the formed microcapsules,
(d) cationization microcapsules cationic polymer or monomer,
(e) the connection or binding of microcapsules to the fibers and/or textile materials
(f) drying the fibers and/or textile materials.

2. A method according to claim 1, which additionally includes cooling microcapsules between step b) and step C).

3. A method according to any one of claims.1-2, where the hydrophilic colloids selected from the group formed by the following: proteins, polysaccharides, polyesters, polycyanoacrylates and/or mixtures thereof.

4. A method according to claim 3, wherein the proteins and polysaccharides selected from the group formed by the following: gelatin, albumin, β-lactoglobulin, milk whey protein, pea protein, potato protein, protein feedstuff beans, wheat protein, bovine serum albumin, poly-L-lysine, soy protein, Caseinates, casein, soya glycine, sodium alginate, wheat starch, corn starch, methylcellulose, ethylcellulose, hydroxypropylmethyl cellulose, cellulose nitrate, carboxymethyl cellulose, gum Arabic, xanthan gum, Mesquite gum, guar gum, carragenan, tragacanth gum, arabinogalactan, galactomannans, hexane�apostat sodium, the exopolysaccharide B40, carboxymethyl sodium, pectin, methoxylation, agar, dextran, chitosan, acetobutyrate cellulose, acatitla cellulose, acrylic derivatives and polyesters, such as poly-ε-caprolactone, Zein, phthalate of hydroxypropylmethylcellulose, acetonuria of hydroxypropylmethylcellulose, polyvinylacetate, poly(p-dioxanone), poly(β-valerolactone), poly(β-hydroxybutyrate), copolymers of poly(β-hydroxybutyrate) and β-hydroxyvalerate, poly(β-hydroxypropionate), copolymers of methylacrylate acid, copolymers of dimethylaminoethylmethacrylate, copolymers of trimethylammoniumchloride, the polymers and copolymers of lactic and glycolic acid, polymers and copolymers of lactic and glycolic acid and polyethylene glycol and mixtures thereof.

5. A method according to any one of claims.1-2, where bring the pH in step (b) is to a pH of from 3 to 5.5.

6. A method according to any one of claims.1-2, where the increase in pH in step C) is to a pH of from 6.5 to 13.

7. A method according to any one of claims.1-2, where Poperechnaya a means selected from the group formed by the following: aldehydes, glutaraldehyde, formaldehyde, transglutaminase, derived methylenebisacrylamide, N,N-methylenebisacrylamide, N,N-(1,2-dihydroxyethylene)bisacrylamide, derivatives of etilenglikolevykh, etilenglikolevye, dietilenglikoluretan, tetraethylorthosilicate, ethylenglycol�of dimethacrylate, diethylethylenediamine, Triethylenetetramine, sodium tripolyphosphate, esters of N-hydroxysuccinimide and/or imidiately.

8. A method according to any one of claims.1-2, where the cationic polymer is selected from the group formed by the following: cationic cellulose derivatives, kvaternikova hydroxyethylcellulose, cationic starches, copolymers of diallylamine acrylamide and salts, quaternion polymers of vinylpyrrolidone/vinylimidazole, condensation products of polyglycols and amines, polymers and copolymers of polyquaternium, polymers having the name of mercuty of polyquaternium-6, polyquaternium-7, polyquaternium-16, polyquaternium-10, copolymers of polyquaternium-4, dicocoylethylenediamine, graft copolymers with a cellulose skeleton and Quaternary ammonium groups, quaternion collagen polypeptides, hydroxypropyltrimonium hydrolyzed collagen, quaternion wheat polypeptides, polyethyleneimine, cationic polymers, silicone midamerican or silicone quaternium-22, copolymers of adipic acid and , copolymers of acrylic acid with dimethyldiallylammonium, cationic chitin derivatives, condensation products of cationic dehalogenation, condensation products of dibromobutane with misdialling, bis-dimethylamino-,3-propane, derivatives of the cationic guar gum, guar-hydroxypropyltrimonium, polymers of Quaternary ammonium salts, quaternion natural polymers polysaccharide derivatives, such as azarosa, cationic gelatin proteins, cationic proteins of gum Arabic, cationic polyamide polymers, cationic polymers of polycyanoacrylate, cationic polymers of polylactide, cationic polymers of polyglycolide, cationic polymers of polyaniline, cationic polymers of polypyrrole, cationic polymers, polyvinylpyrrolidone, cationic polymers are polymers and copolymers of aminosilicones, cationic polymers of polystyrene, cationic polymers of polyvinyl alcohol, cationic copolymers of polystyrene and maleic anhydride, cationic polymers of methyl vinyl ether, cationic polymers epoxy resins, cationic polymers of copolymers of styrene and methyl methacrylate, dimethylaminomethyl, cationic polyacrylates and polymethacrylates, polyamine derivatives, optionally substituted derivatives by members of the polyethylene glycol, polyaminoamide under conditions of pH where they are cationic, polyethyleneimine, quaternion derivatives of polyvinylpyrrolidone and hydrophilic urethane polymers, and any mixture of the above-mentioned cationic groups.

9. A method according to any one of claims.1-2, where the connection or linking is performed using a depletion �Anna, or plyaski, or spraying.

10. A method according to any one of claims.1-2, where the drying is carried out for at least 2 minutes at temperatures higher than 100°C.

11. A method according to any one of claims.1-2, where the active ingredient is selected from the group formed by the following: the active ingredients and/or cosmetic and/or dermofarmatsevtiki auxiliary substances and insect repellents.

12. A method according to claim 11, where the active ingredient and/or cosmetic and/or dermofarmatsevtiki auxiliary substance selected from the group formed by the following: surfactant, wetting means or substances that retain moisture, moisturizers or emollients, agents that stimulate the healing process, facilitate the healing means, stimulating re-epithelialization, a means of contributing to reepithelialization, means that synthesize dermal or epidermal macromolecules, sealing and/or reducing the density and/or restructuring funds, growth factors, cytokines, means acting on capillary circulation and/or microcirculation, artiglierie tools, traps free radicals and/or agents against atmospheric pollution, trap reactive carbonyl species, means of inhibiting 5α-reductase, and means inhibiting lysyl - and/or �tolylhydrazine, means stimulating defensin synthesis, bactericidal agent, and/or a bacteriostatic agent, and/or antimicrobial, and/or germicidal means, and/or fungicidal agents, and/or fungistatic funds, and/or inhibiting pathogenic microorganisms, antiviral agents, antiparasitic agents, antihistamines, means inhibiting NO-synthase, means for peeling or keratolytic remedies and/or remedies to exfoliate, comedolytics funds, antipsoriatic drugs, anti-dandruff, anti-inflammatories and/or analgesics, anaesthetics, anti-wrinkle and/or anti-aging products, cosmetic deodorant and/or absorbent and/or masking body odour deodorants, tools, antiperspirants, fragrances and/or scented oils, and/or selected aromatic compounds, the funds are antioxidants that means that inhibit vascular permeability, hydrolytic epidermal enzymes, bleaching or depigmenting skin, means inhibiting the enzymes the collapse of sweat, means capable of filtering UV rays, means which stimulate or regulate the differentiation of keratinocytes, antipruritic, tools, that stimulate Il� inhibit the synthesis of melanin, coloring means, bronzer, agents that stimulate the proliferation of melanocytes, liquid propellants, vitamins, amino acids, proteins, biopolymers, gelling polymers, drugs to relax the skin, means to reduce or treat bags under eyes, remedies for the treatment and/or care of sensitive skin, tightens pores funds, means of regulating the production of sebum, anti stretch marks, lipolytic funds or a means of stimulating lipolysis, venotonizirutee funds, cellulite remedies, sedatives, agents acting on cell metabolism, a means to improve dermaline-epidermal junction, means of inducing hair growth or slowing down the hair loss, the means of inhibiting or retarding the growth of body hair, a means of stimulating the synthesis of heat shock proteins, muscle relaxers, tools, inhibiting muscle contraction, means inhibiting the aggregation acetylecholine receptors, anticholinergic means, inhibiting elastase, the means of inhibiting a matrix metalloproteinase, a chelating means, plant extracts, essential oils, extracts from marine products, mineral salts, cell extracts, emulsifying means, means stimulating the synthesis of lipid�in and components of the stratum corneum, funds received from the bio-enzymatic method of and/or mixtures thereof.

13. A method according to any one of claims.1-2, where emulsify the active ingredient in the emulsion water-in-oil and suspended in step (a).

14. A method according to claim 13, wherein the emulsion is water-in-oil contained in solid lipid nanoparticles or nanostructured lipid carrier.

15. The fiber and/or textile material obtained according to the method according to any one of claims.1-14.

16. The use of a fiber and/or textile material according to claim 15 for the treatment and/or care of skin, hair and/or scalp.



 

Same patents:

FIELD: medicine.

SUBSTANCE: claimed invention relates to medicine and describes method of obtaining delivering particles of fragrance, containing core material and envelope, said envelope at least partially surrounds said core material and at least 75% of said delivering particles of fragrance are characterised by tensile strength from approximately 0.2 MPa to approximately 10 MPa, with particle size from approximately 1 micron to approximately 80 micron and thickness of particle walls from approximately 60 nm to approximately 250 nm; and said delivering particles of fragrance are characterised by release of fragrance from 0% to approximately 30%. In addition to creation of possibility to reduce number of agent which produces favourable impact, such particles make it possible to extend spectrum of applied agents which produce favourable impact.

EFFECT: in cases of application in compositions, for instance, detergents, or compositions for fabric care, such particles increase efficiency of delivery of agent which produces favourable impact, making it possible to use reduced amounts of agents which produce favourable impact.

11 cl, 9 tbl, 13 ex

FIELD: physics.

SUBSTANCE: sensitive device has at least one first layer having an electroconductive polymer, if necessary, mixed with a binding substance, which forms a matrix of a binding agent, and at least one second layer which lies separately from the first layer near or at a distance or which is at least partially joined to the first layer. The second layer has microcapsules which contain acidic or alkaline substance, if necessary mixed with a binding substance and alters electrical conductivity of the polymer when released from the microcapsules.

EFFECT: making sensitive devices for monitoring state of articles.

40 cl, 1 ex, 2 tbl, 3 dwg

FIELD: self-copy papers.

SUBSTANCE: group of inventions relate to use of microcapsules containing color reaction component. Color reaction component is first dissolved in solvent, namely vegetal oil C1-C8-alkyl ester, and to thus obtained solution a non-solvent is admixed at rapid stirring, said non-solvent not dissolving or dissolving insignificantly color reaction component and being taken in amount as to form supersaturated solution. The latter is directly emulsified in water phase at rapid stirring and, immediately after that, resulting emulsion is processed so that encapsulation takes place therein. Microcapsules obtained in this way are further described as well as their employment in color reaction paper.

EFFECT: improved writing quality and economic and environmental advantages.

33 cl, 1 dwg, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining L-arginine nanocapsules in sodium alginate envelope. In the process of method realisation L-arginine is suspended in benzene. Obtained mixture is dispersed into suspension of sodium alginate in hexane in presence of preparation E472c with mixing at 1000 rev/sec. After that, chloroform is added, and obtained suspension of nanocapsules is filtered and dried at room temperature. Process is realised for 15 minutes.

EFFECT: method in accordance with invention provides simplification and acceleration of process of obtaining nanocapsules and increased output by weight.

3 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry. The method for production of dry girasol extract in pectin envisages usage of a microcapsule shell, represented by low-etherified and high-etherified apple and citrus pectins, and a nucleus, represented by dry girasol extract. The microcapsules are produced by way of the pectin mixture stirring in benzol, with the surfactant represented by preparation E472c, in a magnetic stirrer. Then dry girasol extract is added into the mixture which is deposited with acetonitrile. Then the produced microcapsule suspension is filtered, washed with acetonitrile and dried.

EFFECT: invention allows to simplify and accelerate the microcapsules production process and increase weight yield.

7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to production of glucosamine sulphate nanocapsules in a konjac gum shell. According to the present method, glucosamine sulphate is added in portions to a suspension of a konjac gum in butyl alcohol containing an E472c preparation as a surfactant. The weight ratio of glucosamine sulphate and konjac gum is 1:3. The mixture is stirred. Hexane is then added and the obtained nanocapsule suspension is filtered, washed with hexane and dried. The process is carried out at 25°C for 15 minutes.

EFFECT: method simplifies and speeds up the process of producing nanocapsules in konjac gum and increases mass output.

1 tbl, 2 ex, 1 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to field of encapsulation, in particular to method of obtaining microcapsules of vitamins A, C, E or Q10 in coating from highly etherified or low etherified apple or citrus pectin. In accordance with method by invention preparation E472c is added to suspension of highly etherified or low etherified apple or citrus pectin in ethanol and mixed. After that, suspension of vitamin in dimethylsulphoxide is added to suspension of pectin in ethanol, with further addition of benzene and distilled water. Obtained suspension of microcapsules is filtered and dried. Process of obtaining microcapsules is realised at 25°C for 15 min.

EFFECT: invention provides simplification and acceleration of process of obtaining microcapsules, reduction of loss in the process of their obtaining (increase of output by weight).

16 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of encapsulation, in particular to method of obtaining microcapsules of medications from cephalosporin group in human leukocyte interferon (β- or α-interferon) coat. In accordance to invention cephalosporin powder and E472c preparation are added to 1% water solution of human leukocyte interferon in α- or β-form and mixed until reaction mixture components dissolve. After formation of transparent solution butanol and acetone are added. Obtained suspension of microcapsules is filtered, washed and dried. Process of obtaining microcapsules is realised at 25°C for 15 min.

EFFECT: invention provides simplification and acceleration of process of obtaining microcapsules, reduction of loss in the process of their obtaining (increase of output by weight).

4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of nanocapsulation in obtaining nanocapsules of glucoamine sulphate in xanthan gum envelope. In accordance with invention glucosamine sulphate is added by portions into suspension of xanthan gum in butyl alcohol, containing preparation E472c as surfactant. Mixture is mixed, after that hexane is added, obtained mixture of nanocapsules is filtered, washed with hexane and dried. Process is realised at 25°C for 15 minutes.

EFFECT: method in accordance with invention provides simplification and acceleration of process of obtaining glucosamine sulphate nanocapsules in xanthan gum and increase of output by weight.

2 ex

FIELD: chemistry.

SUBSTANCE: potassium losartan is added by portions into a suspension of xanthane gum in benzene in the presence of the preparation E472 with mixing at 1000 rev/sec. Then hexane is added. The obtained suspension of nanocapsules is filtered and dried at room temperature. The envelope:core ratio constitutes 3:1 or 1:5.

EFFECT: simplification and acceleration of the process of obtaining nanocapsules and an increase of output by weight.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of medicine and describes a method of obtaining ferrocene microcapsules, where xanthan gum is used as an envelope for the microcapsules, characterised by the fact that a suspension of 100 mg of ferrocene in 2 ml of benzene is dispersed into a suspension of xanthan gum in the presence of 0.01 g of E472 c preparation with mixing, with the addition of 5 ml of acetone and 0.5 ml of water; the obtained suspension is filtered and dried at room temperature.

EFFECT: invention provides the simplification and acceleration of the process of obtaining the microcapsules and increase of output by weight.

1 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of encapsulating alkaloids. Said method is characterised by that an alkaloid is dissolved in dioxane, dimethyl sulphoxide or dimethyl formamide, then dispersed in a mixture of sodium carboxymethyl cellulose and acetone in the presence of E472c, adding distilled water, filtering and drying the obtained suspension of microcapsules, wherein the core/polymer ratio in the microcapsules is 1:3.

EFFECT: invention provides a simple and fast process of producing alkaloid microcapsules and increases mass output.

19 ex

FIELD: metallurgy.

SUBSTANCE: under the suggested method of the melts granulation including product melt supply to the liquid inert medium in form of jets flowing from the calibrated holes, with installed needles, the inert medium is melt. Melting temperature of the inert medium is below melting temperature of the granulated material. The obtained product granules are cooled in the inert liquid to temperature (20-30)°C. The inert liquid density is higher than the inert medium density and below the product granules density. The product melting temperature is (1.5-1.25) of melting temperature of the granulated material, and inert medium temperature is (1.05-1.15) of its melting temperature.

EFFECT: increased quality of produced granulated product, and capacity of the process of melt granulation due to contact of the product melt droplets with inert medium in form of the melt heated to temperature below the melting temperature of the granulated material.

3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microencapsulation of water-soluble preparations, particularly to encapsulation of common jujube possessing the therapeutic properties. The method for common jujube encapsulation involves dispersing common jujube powder suspension in isopropanol in the presence of the preparation E472 and precipitating with carbon tetrachloride as a non-solvent. There are produced microcapsules containing common jujube as a core in xanthane gum as a shell in core:shell ratio 1:3, 1:1 and 3:1 with 100% yield.

EFFECT: invention provides simplifying and accelerating the microencapsulation process and higher weight yield.

3 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry. The method for production of dry girasol extract in pectin envisages usage of a microcapsule shell, represented by low-etherified and high-etherified apple and citrus pectins, and a nucleus, represented by dry girasol extract. The microcapsules are produced by way of the pectin mixture stirring in benzol, with the surfactant represented by preparation E472c, in a magnetic stirrer. Then dry girasol extract is added into the mixture which is deposited with acetonitrile. Then the produced microcapsule suspension is filtered, washed with acetonitrile and dried.

EFFECT: invention allows to simplify and accelerate the microcapsules production process and increase weight yield.

7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of encapsulation, in particular to method of obtaining microcapsules of vitamins A, C, E or Q10 in coating from highly etherified or low etherified apple or citrus pectin. In accordance with method by invention preparation E472c is added to suspension of highly etherified or low etherified apple or citrus pectin in ethanol and mixed. After that, suspension of vitamin in dimethylsulphoxide is added to suspension of pectin in ethanol, with further addition of benzene and distilled water. Obtained suspension of microcapsules is filtered and dried. Process of obtaining microcapsules is realised at 25°C for 15 min.

EFFECT: invention provides simplification and acceleration of process of obtaining microcapsules, reduction of loss in the process of their obtaining (increase of output by weight).

16 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of encapsulation, in particular to method of obtaining microcapsules of medications from cephalosporin group in human leukocyte interferon (β- or α-interferon) coat. In accordance to invention cephalosporin powder and E472c preparation are added to 1% water solution of human leukocyte interferon in α- or β-form and mixed until reaction mixture components dissolve. After formation of transparent solution butanol and acetone are added. Obtained suspension of microcapsules is filtered, washed and dried. Process of obtaining microcapsules is realised at 25°C for 15 min.

EFFECT: invention provides simplification and acceleration of process of obtaining microcapsules, reduction of loss in the process of their obtaining (increase of output by weight).

4 ex

FIELD: chemistry.

SUBSTANCE: potassium losartan is added by portions into a suspension of xanthane gum in benzene in the presence of the preparation E472 with mixing at 1000 rev/sec. Then hexane is added. The obtained suspension of nanocapsules is filtered and dried at room temperature. The envelope:core ratio constitutes 3:1 or 1:5.

EFFECT: simplification and acceleration of the process of obtaining nanocapsules and an increase of output by weight.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of medicine and describes a method of obtaining ferrocene microcapsules, where xanthan gum is used as an envelope for the microcapsules, characterised by the fact that a suspension of 100 mg of ferrocene in 2 ml of benzene is dispersed into a suspension of xanthan gum in the presence of 0.01 g of E472 c preparation with mixing, with the addition of 5 ml of acetone and 0.5 ml of water; the obtained suspension is filtered and dried at room temperature.

EFFECT: invention provides the simplification and acceleration of the process of obtaining the microcapsules and increase of output by weight.

1 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of encapsulating alkaloids. Said method is characterised by that an alkaloid is dissolved in dioxane, dimethyl sulphoxide or dimethyl formamide, then dispersed in a mixture of sodium carboxymethyl cellulose and acetone in the presence of E472c, adding distilled water, filtering and drying the obtained suspension of microcapsules, wherein the core/polymer ratio in the microcapsules is 1:3.

EFFECT: invention provides a simple and fast process of producing alkaloid microcapsules and increases mass output.

19 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of microencapsulation, in particular to a method of obtaining microcapsules of medications of a cephalosporin group. The method is characterised by the fact that human serum albumin is used as an envelope for microcapsules, with the addition to a water solution of albumin of a powder of a cephalosporin group preparation in the presence of a surface-active substance E472c, the ratio of quantity of the cephalosporin group preparation to albumin counted per dry substance constitutes from 1:1 to 3:1, the obtained mixture is mixed to the complete dissolution of components with the slow drop-by-drop addition of butanol as the first precipitating agent, and then acetone as the second precipitating agent, the obtained suspension of microcapsules is filtered, washed with acetone, dried in a dessicator, the process of obtaining microcapsules is realised at 25°C.

EFFECT: method provides the simplification and acceleration of the process of obtaining microcapsules of the water-soluble medications of a cephalosporin group in human serum albumin, and reduction of loss in obtaining the microcapsules.

3 ex

Up!